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resumo 
 
 
A curcumina é um pigmento de cor amarela, da família dos polifenóis, obtido a 
partir dos rizomas da planta Curcuma longa. É dotada de diversas propriedades 
biológicas que se relacionam com a vasta gama de alvos moleculares que 
possui, sendo de destacar a sua atividade anticancerígena já provada em 
diversas linhas celulares cancerígenas. No entanto, a atividade biológica da 
curcumina é limitada pela sua baixa biodisponibilidade que se deve 
principalmente à sua fraca solubilidade e rápida degradação em condições 
fisiológicas. Uma estratégia para contornar as limitações terapêuticas da 
curcumina é a sua complexação com iões metálicos, nomeadamente com 
complexos de ruténio(II).  
Neste trabalho foi preparado um novo complexo de curcumina com ruténio(II) e 
tritiaciclononano [9anoS3] com o objetivo de aumentar a solubilidade da 
curcumina em meio fisiológico. A curcumina foi extraída e purificada a partir de 
rizomas secos e pulverizados de Curcuma longa sendo depois desprotonada e 
coordenada com o precursor [Ru(II)(9anoS3)(DMSO)Cl2] 
(DMSO=dimetilsulfóxido). A estrutura e pureza do complexo formado, 
[Ru(II)(9aneS3)(curcumina)(S-DMSO)]Cl foi avaliada por Ressonância 
Magnética Nuclear de 1H e 13C, espectrometria de massa e análise elementar. 
A afinidade do novo complexo para ligação ao ácido desoxirribonucleico (ADN) 
foi estudada por ensaios de titulação e por determinação da variação na 
temperatura de desnaturação do ADN de esperma de salmão. Este estudo 
permitiu determinar que o complexo tem a capacidade de intercalar com o ADN 
com uma constante de ligação comparável aos intercaladores de ADN já 
conhecidos (4.00x105 M-1). A atividade citotóxica deste complexo contra o 
cancro de próstata foi estudada in vitro, usando como controlo positivo a 
curcumina. Mais ainda, aproveitando o potencial fotossensibilizador da 
curcumina, os ensaios foram feitos na presença e na ausência de luz. Para isso, 
usaram-se culturas celulares humanas isoladas de carcinoma de próstata (PC-
3) e a toxicidade foi avaliada em linhas celulares prostáticas não tumorais (PNT-
2). Com estes ensaios verificou-se que o complexo preparado não tem efeito 
citotóxico nem fototóxico nas concentrações usadas para as linhas celulares 
estudas. Mais, observou-se que a curcumina apresenta, no escuro, efeito 
citotóxico nas concentrações usadas e ainda, que este efeito é fortemente 
potenciado na presença de luz, sendo um potencial agente para terapia 
fotodinâmica em cancro de próstata. 
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abstract 
 
Curcumin is a yellow pigment, of the family of polyphenols, obtained from the 
rhizomes of the Curcuma longa. It is provided with several biological properties 
which relate with the wide range of molecular targets that possesses, especially 
the anticancer activity already proven in various cell lines. However, the 
biological activity of curcumin is limited by their low bioavailability which is mainly 
because their poor solubility and rapid degradation in physiological conditions. 
One promising strategy to circumvent the therapeutic limitations of curcumin is 
the binding with metal ions, namely with ruthenium(II) complexes. 
In this work, was prepared a new complex of curcumin with ruthenium(II) and 
trithiacyclononane (9aneS3) with the aim of increasing the solubility of curcumin 
in physiological medium. The curcumina was extracted and purified from the 
powder rhizomes of Curcuma longa being after deprotonated and coordinated 
with the precursor [Ru(II)(9aneS3)(DMSO)Cl2] (DMSO=dimethylsulfoxide). The 
structure and purity of the prepared complex, [Ru(II)(9aneS3)(curcumina)(S-
DMSO)]Cl was evaluated by 1H and 13C Nuclear Magnetic Resonance 
spectroscopies, mass spectrometry and elemental analysis. The affinity of the 
new complex to bind to deoxyribonucleic acid (DNA) was studied by titration 
assays and determination of the variation on sperm salmon DNA melting 
temperature. This study allowed to determine that the complex has ability to 
intercalate with DNA with a binding constant comparable with classical 
intercalators. The cytotoxic activity of this complex against prostate cancer was 
studied in vitro, using curcumin as a positive control. Moreover, taking advantage 
of the photosensitizer potential of curcumin, the assays were made under dark 
and light conditions. For this, human cell cultures were used isolated from 
prostate carcinoma (PC-3) and the toxicity was evaluated in non-tumour prostate 
cells (PNT-2). With these tests, it was found that the new complex do not have 
any cytotoxic or phototoxic effect in the same concentrations range tested for cell 
lines studied. Further, was observed that the curcumin presents, in dark, 
cytotoxic effect and, that this effect is strongly potentiated by light presence, with 
a potential for photodynamic therapy in prostate cancer.  
 
  
   
 viii 
Contents 
Contents ......................................................................................................................... viii 
List of figures ..................................................................................................................... x 
List of tables ................................................................................................................... xiv 
List of Abbreviations, symbols and acronyms ................................................................. xvi 
1. Introduction ................................................................................................................ 1 
1.1. Curcuma longa Linn ............................................................................................ 1 
1.1.1. Extraction, purification and identification of curcuminoids ............................ 2 
1.2. Curcumin ............................................................................................................ 3 
1.2.1. Molecular targets ......................................................................................... 6 
1.2.2. Bioavailability ............................................................................................... 7 
1.2.3. Binding to metals and effects on stability, bioavailability and cytotoxicity ..... 8 
1.3. Metal complexes in cancer treatment.................................................................11 
1.3.1. Platinum complexes ....................................................................................12 
1.3.2. Ruthenium complexes ................................................................................13 
1.4. Cancer ...............................................................................................................15 
1.5. Prostate cancer .................................................................................................16 
1.6. Photodynamic therapy in cancer treatment ........................................................18 
1.6.1. Curcumin in photodynamic therapy .............................................................19 
1.7. Aims of this work ...............................................................................................20 
2. Experimental section ................................................................................................23 
2.1. Equipment .........................................................................................................23 
2.2. Materials ............................................................................................................24 
2.3. Methods .............................................................................................................25 
2.3.1. Extraction and isolation of curcumin ...........................................................25 
2.3.2. Preparation of [Ru([9]aneS3)(curcumin)(S-DMSO)]Cl complex (Ru-curc 
complex) ...................................................................................................................26 
2.3.3. Fluorescence quantum yield .......................................................................27 
2.3.4. Singlet oxygen measurements ....................................................................27 
2.3.5. DNA binding studies ...................................................................................28 
2.3.6. Biological assays ........................................................................................30 
2.3.7. Statistical analysis ......................................................................................32 
3. Results and discussion .............................................................................................33 
3.1. Extraction and isolation of curcumin ..................................................................33 
3.2. Ruthenium(II)-trithiacyclononane complex with curcumin...................................35 
 ix 
3.3. Photophysical properties....................................................................................39 
3.3.1. Absorption spectra ......................................................................................39 
3.3.2. Fluorescence spectra .................................................................................40 
3.4. Singlet oxygen studies .......................................................................................41 
3.5. DNA binding studies ..........................................................................................42 
3.5.1. Absorption spectral studies .........................................................................43 
3.5.2. Thermal denaturation of DNA .....................................................................45 
3.6. Biological evaluation ..........................................................................................47 
3.6.1. Cellular Viability ..........................................................................................47 
4. Conclusions and future prospects .............................................................................56 
4.1. Conclusions .......................................................................................................56 
4.2. Future prospects ................................................................................................57 
References ......................................................................................................................59 
Appendix ..........................................................................................................................77 
Appendix 1: Calibration curves .....................................................................................77 
 
  
 x 
List of figures 
Figure 1 - Chemical structures of the three curcuminoids present in the plant 
Curcuma longa L. ........................................................................................................... 2 
Figure 2 - Keto-enol tautomeric equilibrium of curcumin. ........................................... 4 
Figure 3 - Curcumin degradation products after exposure to light. ............................ 5 
Figure 4 - Human diseases against which curcumin has exhibited activity. Adapted 
from He and collaborators.43 ............................................................................................. 5 
Figure 5 – Synthesis of [Ruthenium(II)(R)(curcumin)X] complexes already tested in 
several human tumour and non-tumour cell lines. Where, R=p-cymene, benzene or 
hexamethylbenzene and X=Cl or PTA. i) NaOCH3, MeOH................................................ 9 
Figure 6 - Platinum complexes approved worldwide for clinical use. ........................12 
Figure 7 – Ruthenium(III) based anticancer complexes NAMI-A and KP1019 in clinical 
trials ................................................................................................................................14 
Figure 8 - Structure of macrocyclic ligand 1,4,7-trithiacyclononane ([9]aneS3). .......14 
Figure 9 - Molecular structure of [Ru(II)(9aneS3)(S-DMSO)Cl2]. ..................................15 
Figure 10 - Photobleaching reaction of 9,10-dimethylanthracene by 1O2 ..................28 
Figure 11 – Carbon labeling scheme for the curcumin ...............................................34 
Figure 12 - 1H NMR spectrum recorded in CDCl3 for the curcumin ............................34 
Figure 13 - 13C NMR spectrum recorded in CDCl3 of curcumin. .................................35 
Figure 14 – Reactional scheme for the two-step synthesis of Ru-curc complex. .....36 
Figure 15 - 1H NMR spectrum recorded in CDCl3 of Ru-curc complex. ......................37 
Figure 16 - 13C NMR spectrum recorded in CDCl3 of the Ru-curc complex. ..............38 
Figure 17 – Normalized UV-Vis absorption spectra of curcumin and Ru-curc complex 
in DMF and DMSO at 25 ºC. ...........................................................................................40 
Figure 18 - Normalized fluorescence emission spectra (λexc 430 nm) of curcumin and 
Ru-curc complex in DMF. ..............................................................................................41 
Figure 19 - First-order plots for the photooxidation of DMA (30 μM) photosensitized 
by TPP (green squares), curcumin (yellow triangles) and Ru-curc complex (grey 
crosses) in DMF, under irradiation at 430 nm at the irradiance of 30 mW/cm2. Values 
represent mean ± standard deviation of three independent experiments. ........................42 
Figure 20 – UV-Vis absorption spectra of curcumin (30 μM) with increasing 
concentrations of sp-DNA in PBS. ...............................................................................44 
Figure 21 – UV-Vis absorption spectra of Ru-curc complex (30 μM) with increasing 
concentrations of sp-DNA in PBS. ...............................................................................44 
 xi 
Figure 22 - Comparison of the thermal denaturation curves for pure sp-DNA (grey), 
sp-DNA/curcumin (orange) and sp-DNA/Ru-curc complex (blue) mixtures in 10:1 
molar ratio. Curves were recorded under equilibrium conditions in 10 mM PBS at pH 7.2.
 ........................................................................................................................................46 
Figure 23 - Alamar Blue (AB) assay for PNT-2 cell viability. PNT-2 cells were seeded at 
varying densities in a 96-well plate. The AB solution (10% of cell culture volume) was added 
to the plate and relative absorbance units at 540 and 630 nm were measured at 1, 2, 4, 6, 
8 and 24 h. .......................................................................................................................47 
Figure 24 - Alamar Blue (AB) assay for PC-3 cell viability. PC-3 cells were seeded at 
varying densities in a 96-well plate. The AB solution (10% of cell culture volume) was added 
to the plate and relative absorbance units at 540 and 630 nm were measured at 1, 2, 4, 6, 
8 and 24 h. .......................................................................................................................48 
Figure 25 - Effect of curcumin and Ru-curc complex on cell viability of PNT-2 cell line. 
PNT-2 cells were treated with different concentrations of curcumin, Ru-curc complex or 
vehicle control DMSO at 1% for 72 h at 37 ºC in dark. The AB assay was used to determine 
cell viability. Data are representative of three independent trials and are expressed as the 
mean ± SD. *P-value<0.05 and **P-value<0.001, compared to the group control. ...........49 
Figure 26 - Effect of curcumin and Ru-curc complex on cell viability of PC-3 cell line. 
PC-3 cells were treated with different concentrations of curcumin and Ru-curc complex or 
vehicle control DMSO at 1% for 72 h at 37 ºC in Dark. The AB assay was used to determine 
cell viability. Data are representative of three independent trials and are expressed as the 
mean ± SD. **P-value<0.001 and ****P-value<0.0001, compared to the group control. ...49 
Figure 27 - Effect of curcumin on cell viability of PNT-2 and PC-3 cell lines in dark 
conditions. PNT-2 and PC-3 cells were treated with different concentrations of curcumin 
or vehicle control DMSO at 1% for 72 h at 37 ºC in dark conditions. The AB assay was used 
to determine cell viability. Data are representative of three independent trials and are 
expressed as the mean ± SD. *P-value<0.05, **P-value<0.001 and ****P-value<0.0001, 
compared to the group control. ........................................................................................50 
Figure 28 - Effect of curcumin on cell viability of PNT-2 cell line in dark and with 
irradiation. PNT-2 cells were treated with different concentrations of curcumin or vehicle 
control DMSO at 1% for 72 h at 37 ºC in dark or with irradiation. The AB assay was used to 
determine cell viability. Data are representative of three independent trials and are 
expressed as the mean ± SD. *P-value<0.05, **P-value<0.001 and ****P-value<0.0001, 
compared to the group control. ........................................................................................51 
 xii 
Figure 29 – Effect of curcumin on cell viability of PC-3 cell line in dark and with 
irradition. PC-3 cells were treated with different concentrations of curcumin or vehicle 
control DMSO at 1% for 72 h at 37 ºC in Dark or with irradiation whit white light at an 
irradiance of 10 mW/cm2 and a total light dose of 6 J/cm2. The AB assay was used to 
determine cell proliferation. Data are representative of three independent trials and are 
expressed as the mean ± SD. *P-value<0.05, **P-value<0.001 and ****P-value<0.0001, 
compared to the group control. ........................................................................................52 
Figure 30 - Effect of curcumin on cell viability of PNT-2 and PC-3 cell lines in light 
conditions. PNT-2 and PC-3 cells were treated with different concentrations of curcumin 
or vehicle control DMSO at 1% for 72 h at 37 ºC in light conditions. The AB assay was used 
to determine cell viability. Data are representative of three independent trials and are 
expressed as the mean ± SD. **P-value<0.001 and ****P-value<0.0001, compared to the 
group control. ...................................................................................................................53 
Figure 31 - Effect of Ru-curc complex on cell viability of PNT-2 cell line. PNT-2 cells 
were treated with different concentrations of Ru-curc complex or vehicle control 1% DMSO 
for 72 h in dark or exposure to white light at an irradiance of 10 mW/cm2 and a total light 
dose of 6 J/cm2 light dose. The AB assay was used to determine cell proliferation. Data are 
representative of three independent trials and are expressed as the mean ± SD. ............54 
Figure 32 - Effect of Ru-curc complex on cell viability of PC-3 cell line. PC-3 cells were 
treated with different concentrations of Ru-curc complex or vehicle control 1% DMSO for 72 
h in dark or exposure to white light at an irradiance of 10 mW/cm2 and a total light dose of 
6 J/cm2 light dose. The AB assay was used to determine cell viability. Data are 
representative of three independent trials and are expressed as the mean ± SD. ............54 
Figure 33 – Examples of O-coordinated ligands with ruthenium(II) metal centers. 
FL=flavonate. ...................................................................................................................56 
 
Figure A 1 – Calibration curve for determination of the molar absorptivity of the 
curcumin in DMSO. ........................................................................................................77 
Figure A 2 – Calibration curve for determination of the molar absorptivity of the 
curcumin in DMF. ...........................................................................................................77 
Figure A 3 – Calibration curve for determination of the molar absorptivity of the Ru-
curc complex in DMSO. .................................................................................................78 
Figure A 4 - Calibration curve for determination of the molar absorptivity of the Ru-
curc complex in DMF. ....................................................................................................78 
 xiii 
  
 xiv 
List of tables 
Table 1 - Molecular targets and cell processes modulated by curcumin. Curcumin 
interacts directly or indirectly with various molecular targets, including transcription factors, 
growth factors, receptors, cytokines, anti-apoptotic proteins, pro-apoptotic proteins, 
enzymes, protein kinases, and adhesion molecules, altering their expression. ................. 6 
Table 2 – Cytotoxic activities of curcumin and [Ru(II)(R)(curcumin)X] complexes 
described in literature, where R= p-cymene, benzene or hexamethylbenzene and X= 
Cl or PTA. IC50 values of complexes in human cell lines. Cisplatin was tested as a positive 
control. .............................................................................................................................11 
Table 3 - Potential targets for prostate cancer chemoprevention. .............................18 
Table 4- 1H NMR chemical shifts for the ligand curcumin and the Ru-curc complex in 
CDCl3. .............................................................................................................................37 
Table 5 - 13C NMR chemical shifts for the ligand curcumin and the Ru-curc complex.
 ........................................................................................................................................39 
Table 6 - Kinetic parameters, Kobs (s-1) of the photooxidation reaction of DMA by TPP, 
curcumin and Ru-curc complex after exposure to light of 430 nm at the irradiance of 
30 mW/cm2 and 1O2 quantum yield in DMF...................................................................42 
Table 7 Ligand-based absorption spectral properties and binding constant of 
compounds to sp-DNA. .................................................................................................45 
Table 8 – Comparison of thermal denaturation for pure sp-DNA, sp-DNA/curcumin or 
sp-DNA/Ru-curc complex mixtures. The values for Tm were obtained from the midpoint 
of melting curves for pure sp-DNA, sp-DNA/curcumin and sp-DNA/Ru-curc complex 
mixtures (10:1). ................................................................................................................46 
Table 9 - The IC50 values (μM) of curcumin and Ru-curc complex towards PNT-2 and 
PC-3 cell lines with and without light exposure...........................................................55 
  
 xv 
  
 xvi 
List of Abbreviations, symbols and acronyms  
 
δ chemical shift (ppm) 
ΦF fluorescence quantum yields 
ΦΔ singlet oxygen quantum yields 
13C NMR carbon Nuclear Magnetic Resonance 
1H NMR proton Nuclear Magnetic Resonance 
J coupling constant 
1J coupling constant over one bonds 
2J coupling constant over two bonds 
3J coupling constant over three bonds 
1O2 singlet state of oxygen 
3O2 triplet state of oxygen 
A2780 human ovarian cancer cell line 
A2780cisR human ovarian platinum-resistant cancer cell line 
A431 human epidermoid carcinoma cell line 
A549 human lung adenocarcinoma cell line 
AB alamarblue 
A absorbance 
ADT androgen-deprivation therapy 
AMC-HN3 human head and neck cancer cell line 
AP-1 activator protein 1 
AR androgen receptor 
AUC integrated area under the fluorescence curves 
Bax b-cell lymphoma 2-associated X protein 
Bcl-2 b-cell lymphoma 2 
Bcl-XL b-cell lymphoma-extra large 
CC column chromatography 
CDCl3 deuterated chloroform 
Cyclin-CDK cyclin dependent kinase complex 
CNE1 human nasopharyngeal carcinoma cell line 
CNE2 human nasopharyngeal carcinoma drug-resistant cell line 
 xvii 
COSY homonuclear correlation spectroscopy (1H/1H) 
COX-2 cyclooxygenase-2 
d doublet 
dd doublet of doublets 
DMA 9,10-dimethylanthracene 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DRE digital rectal examination 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
ESI-MS electrospray ionization mass spectrometry 
FBS fetal bovine serum  
FDA food and drug administration  
FGF fibroblast growth factor 
FGFR fibroblast growth factor receptor 
GFR growth factor receptor 
HaCaT aneuploid immortal keratinocyte cell line 
HCT116 human colon cancer cell line 
HEK293 human embryonic kidney cell line 
HMBC heteronuclear multiple bond correlation (13C/1H) 
HPLC high performance liquid chromatography 
HSQC heteronuclear single quantum correlation (13C/1H) 
Hz hertz 
IC50 drug concentration needed to reduce cell viability by 50% 
IL Interleukin 
iNOS inducible nitric oxide synthase 
JNK c-jun N-terminal kinase 
Kb binding constant 
Kobs observed rate constant 
KP1019 trans-[tetrachlorobis(1H-indazole)ruthenate(III)] 
LNCaP lymph node carcinoma of the prostate 
 xviii 
m multiplet 
MAPK mitogen activated protein kinase 
MCF7 breast cancer cell line 
MeOH methanol 
MMP matrix metalloproteinase 
MS mass spectrometry 
NAMI-A new antitumour metastasis inhibitor A 
NaOCH3 sodium methoxide  
NF-kB nuclear factor kappa B 
Nfr-2 nuclear factor erythroid 2-related factor 2 
NMR nuclear magnetic resonance 
OD optical density 
OMe methoxyl group 
PBS phosphate buffered saline 
PC-3 prostate cancer cell line 
PCa prostate cancer 
PDGF platelet-derived growth factor 
PDGFR platelet-derived growth factor receptor 
PDT photodynamic therapy 
PKA protein kinase A 
PNT-2 prostatic epithelial cell line 
PPAR-γ peroxisome proliferator-activated receptor gamma 
ppm parts per million 
PS photosensitizer 
PSA prostate-specific antigen 
PTA 1,3,5-triaza-7-phosphoadamantane 
Rf retardation factor 
ROS reactive oxygen species 
RPMI roswell park memorial institute 
Ru(II) ruthenium(II) 
Ru-curc [ru([9]anes3)(curcumin)(S-dmso)]Cl complex 
s singlet 
 xix 
S-DMSO dimethylsulfoxide coordinated by the sulphur atom 
sp-DNA deoxyribonucleic acid of salmon sperm 
STAT-3 signal transducer and activator of transcription 3 
TB trypan blue 
TLC thin-layer chromatography 
Tm melting temperature 
TMS tetramethylsilane 
TNF tumour necrosis factor 
TPP 5,10,15,20-tetraphenylporphyrin 
tPSA total prostate-specific antigen 
TRUS transrectal ultrasonography 
U87 human primary glioblastoma cell line 
USA United States of America 
UV-Vis ultraviolet-visible spectroscopy 
VEGF vascular endothelial growth factor 
  1. Introduction 
 
1 
1. Introduction 
 
1.1. Curcuma longa Linn 
Curcuma longa L., commonly known as turmeric or saffron-of-India, is a 
perennial plant of the Zingiberaceae family.1,2 This plant is widely grown in South 
and Southeast Asia, especially in China and India. The part of the plant that is 
usually used is the rhizome, which can be eaten fresh or dried.3 The use of Curcuma 
longa L. rhizomes is referred in Ayurvedic medicine (the characteristic medicinal 
system of Ancient India) as a home remedy for various diseases.4 Currently, 
turmeric is considered as a functional food because of the therapeutic properties of 
their active components, namely anti-inflammatory, antioxidant and anticancer 
activity. This plant is also effective in the treatment of circulatory, liver and 
dermatological diseases (e.g., psoriasis).5,6  
The powder extracted from the dried rhizome of turmeric has a yellow colour 
and its chemical composition is influenced by various factors, such as the 
geographical origin of the plant, the climate of farming, the environment and soil 
composition. It contains mainly starch and, in a lesser extent, proteins, lipids, fibres, 
curcuminoids, and essential oils, such as the α-phellandrene (1%), the sabinene 
(0.6%), the cineole (1%), the borneol (0.5%), the zingiberene (25%), and the 
sesquiterpenes (53%).7,8 The essential oils have been isolated from Curcuma longa 
by distillation by steam entrainment. The curcuminoids, in amounts varying between 
2% and 9% of the turmeric powder, are the active substances of the plant and 
comprise three structurally related phenolic compounds: [(1E,6E)-1,7-bis(4-
hydroxy-3-methoxyphenyl)-hepta-1,6-diene-3,5-dione)], known under the 
designation of curcumin, desmethoxycurcumin [(1E,6E)-1-(4-hydroxy-3-
methoxyphenyl)-7-(4-hydroxyphenyl)-hepta-1,6-diene-3,5-dione)] and 
bisdesmethoxycurcumin [(1E,6E)-1,7-bis(4-hydroxyphenyl)-hepta-1,6-diene-3,5-
dione] (Figure 1).9 The commercially available curcumin is a mixture of these three 
curcuminoids, in which the most abundant constituent is the  curcumin (~77%), 
followed by desmethoxycurcumin (~18%) and the less abundant 
bisdesmethoxycurcumin (~5%).10,11  
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Figure 1 - Chemical structures of the three curcuminoids present in the plant Curcuma 
longa L. 
  
Curcuminoids have an intense yellow colour and are poorly soluble in water 
at physiological and acidic pH, but easily soluble in alkaline solutions.12 They are 
quite soluble in dimethylsulfoxide (DMSO), acetone, dichloromethane, methanol 
and ethanol. These pigments are sensitive to light, high temperature and oxidative 
conditions, decomposing easily.13  
 
1.1.1. Extraction, purification and identification of curcuminoids 
The biological relevance of curcuminoids pigments led to the development of 
several methods for their extraction, separation and identification. The conventional 
extraction methods are based on the combined maceration with ultrasound, heat, 
pressure or enzymatic treatment.14–18 Another way to obtain the compounds is to 
use a Soxhlet apparatus, allowing extraction and filtration to be done in the same 
step.19 However, all methods require long extraction times, high energy 
consumption and high volume of organic solvent. In addition, they exhibit low 
extraction efficiency and losses with heat because curcuminoids are heat-sensitive 
substances. New extraction methods more adapted to this reality, such as 
microwave-assisted extraction, are under development.20  
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Once extracted, the pigments can be separated by thin-layer 
chromatography (TLC),7,10,21 column chromatography (CC)10,22 and high 
performance liquid chromatography (HPLC).10,23 CC has been the most commonly 
employed method for separating curcumin from turmeric. In CC, the mixture of 
curcuminoids adsorbed in silica gel is eluted using mixtures of organic solvents, 
such as dichloromethane/ethyl acetate or methanol/chloroform. The evaluation of 
the purity of the separated compounds can be made by ultraviolet-visible (UV-Vis) 
spectrophotometry but the HPLC is the most used technique.24,25 Typically, reverse 
phase columns with 18 carbons are used, as well as acetonitrile/water or 
chloroform/methanol solvent mixtures as the mobile phase. 
 
1.2. Curcumin 
Curcumin has a scientific history of nearly two centuries that began in 1815, 
date of the first report of its isolation from the rhizome of Curcuma longa, being 
described simply as "a matter of yellow color".26 Later, it was found that this extract 
was in fact a mixture of various curcuminoids with oils and resins derived from 
curcuma rhizomes. In 1870, Daube27 found a method to isolate curcumin in the pure 
and crystalline form and described the crystals he observed under the optical 
microscope. Its chemical structure only was determined in 1910 by Milobedzka and 
Lampe.28 In 1913, it was reported a well succeeded preparation of curcumin in 
laboratory for the first time.29 The curcumin research then slowed and the 
resurgence of curcumin interest emerged in the year 1987 when Kuttan and his 
colleagues30 reported that this polyphenolic compound had anticancer activity. 
Since then, the research for characterization and isolation of this compound has 
increased rapidly.31  
The structure of curcumin consists of two methoxyl groups linked to each 
other, at the orto position of the phenolic rings, which are linked together by a hepta-
unsaturated bridge.32 In fact, it is an α,β-unsaturated β-diketo bridge that exhibits 
keto-enol tautomerism and can exist in different types of conformers depending on 
the nature of the solvent where it is dissolved (Figure 2).32,33 Yellow curcumin 
changes to dark red colour at alkaline pH and under physiological conditions the 
λmáx for curcumin is observed at 420 nm.34 
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Figure 2 - Keto-enol tautomeric equilibrium of curcumin. 
 
The degradation kinetics of curcumin under various pH conditions and its 
stability in physiological matrices are already reported.35 When curcumin was 
incubated in 0.1 M phosphate buffer (PBS), pH 7.2, approximately 90% 
decomposed within 30 min. Moreover, on exposure to light curcumin degrades into 
several products, namely trans-6-(4’-hydroxy-3’-methoxyphenyl)-2,4-dioxo-5-
hexanal, ferulic acid, feruloyl methane and vanillin (Figure 3).35,36 Under acidic 
conditions, the degradation of curcumin is much slower, with less than 20% of total 
curcuminoids decomposed after 1 h. Degradation of curcumin has also been 
demonstrated upon addition to cultured cells.35 Further, it is known that the 
degradation products resulting from the photodegradation of curcumin are the same 
as occur during chemical degradation of the polyphenol. However, the degradation 
is significantly decreased when curcumin is attached to lipids, liposomes, albumins, 
cyclodextrin, surfactants, polymers and many other systems.  
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Figure 3 - Curcumin degradation products after exposure to light. 
 
As indicated above, curcumin possesses several biological properties, 
namely anti-inflammatory,37,38 antioxidant39,40 and anticancer effects.41,42 Therefore, 
curcumin is able to act as a chemopreventive agent, as well as a potential 
therapeutic agent for the many organ and tissue chronic disorders (Figure 4). 
 
 
Figure 4 - Human diseases against which curcumin has exhibited activity. Adapted from He 
and collaborators.43 
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1.2.1. Molecular targets 
The studies published in the last three decades show that the curcumin 
molecule is highly pleiotropic, i.e. capable of modulating the biological activity of a 
series of signalling molecules, affecting many signalling pathways (Table 1).44,45  
 
Table 1 - Molecular targets and cell processes modulated by curcumin. Curcumin interacts 
directly or indirectly with various molecular targets, including transcription factors, growth factors, 
receptors, cytokines, anti-apoptotic proteins, pro-apoptotic proteins, enzymes, protein kinases, and 
adhesion molecules, altering their expression.  
Family Molecular target 
Effect of curcumin in  
molecule activity 
Reference 
Transcriptional factors 
NF-kB ↓ 46 
AP-1 ↓ 47,48 
Nrf-2 ↑ 49 
PPAR-γ ↑ 50 
STAT-3 ↓ 51–53 
Inflammatory cytokines 
TNF-α ↓ 54 
IL-1,2,5,6,8,12,18 ↓ 55,56 
Growth factors 
PDGF ↓ 57 
EGF ↓ 58 
FGF ↓ 59,60 
VEGF ↓ 61–63 
Receptors 
AR ↓ 64,65 
EGFR ↓ 50,66–68 
Kinases 
PKA ↓ 69 
MAPK ↓ 69 
JNK ↓ 70 
Enzymes 
iNOS ↓ 71 
MMP ↓ 72,73 
COX-2 ↓ 74 
Telomerase ↓ 75 
Anti-apoptotic proteins 
Bcl-2 ↓ 76–79 
Bcl-XL ↓ 76–78,80 
Pro-apoptotic proteins 
Bax ↑ 76–79 
Caspase 3 ↑ 81,82 
List of abbreviations on pages xvi-xix. Upward arrows – increased activity; downward arrows – 
decreased. 
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This curcumin feature is directly related to its ability to regulate many targets 
either by direct interaction with transcription factors, growth factors and their 
receptors, nuclear factors, hormones and hormone receptors, cytokines, or by 
controlling the expression of genes that regulate cell proliferation and apoptosis.83 
Curcumin may associate with serum albumin through hydrophobic interactions,84 
being transported to cells where it exerts its pharmalogical effects. Curcumin enters 
the cytoplasm and is able to accumulate in the plasma membrane, endoplasmic 
reticulum and nuclear envelope.85 The complexity of the mechanisms associated 
with the action of curcumin justify its efficiency in combating various multifactorial 
diseases, such as cancer, metabolic diseases and others, as indicated above. 
Curcumin can act against three important steps in carcinogenesis, tumour 
promotion, angiogenesis and tumour growth by modulation of several molecular 
targets. 
 
1.2.2. Bioavailability 
Despite the wide range of biological activities of curcumin, some studies 
report limitations its use as a therapeutic agent, mainly due to its poor bioavailability. 
Curcumin has a relatively low absorption rate at the intestine, undergoes rapid 
metabolism in liver and has a short biological half-life.86 Curcumin is metabolized by 
both conjugation and reduction pathways in the body resulting in formation of 
several metabolites. Furthermore, this low bioavailability is further enhanced by the 
poor solubility of curcumin in water and in physiological conditions, like many other 
natural polyphenols. The kinetics and availability of curcumin in vivo have quite 
distinct profiles depending on the administration routes.  
Oral intake of curcumin is the most common form of contact with this 
compound given that it is typically incorporated into food. Nevertheless, the 
bioavailability of curcumin administered by this route is extremely poor.8 Less than 
1% of oral curcumin enters in the plasma and the small amount of curcumin 
absorbed is subjected to conjugations, like sulfation and glucuronidation in the liver. 
The major reasons for this are the very low solubility at physiological conditions, the 
poor absorption in the body, the rapid metabolism with short biological half-life and 
the rapid systemic elimination.87,88 The poor absorption following oral administration 
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of curcumin implies that very high doses (>3.6 g per day in humans) are required to 
produce any medicinal effect. Studies have shown that 99% of the curcumin found 
in plasma is in the form of glucuronide conjugates,89,90 and that most of these are 
biologically inactive. Indeed, many studies highlight the issue of having extremely 
low concentrations of free curcumin in booth plasma and urine after oral 
administration.91 There are several published methods suggesting that low 
bioavailability of oral curcumin could be circumvent. These include the use of 
adjuvants like piperine,92 curcumin structural analogues,93 and development of 
improved delivery technologies, such as polymeric micelles94 and nanoparticles.95 
Additionally, parenteric forms – intraperitoneal, intravenous, intramuscular 
and subcutaneous - are under development. These require specific formulations to 
stabilize curcumin in an aqueous matrix.89,96–102 Several formulations available, 
allowing repeated systemic injections of curcumin reported in preclinical studies for 
intraperitoneal, intravenous, intramuscular and subcutaneous administration, 
proved that these formulations offer platforms for this otherwise poorly soluble drug. 
 
1.2.3. Binding to metals and effects on stability, bioavailability and 
cytotoxicity 
The use of natural products as ligands for coordination with metal ions has 
been subject of intensive research, since several metal ions allow to mitigate the 
inherent limitations of natural compounds. The metal ions allow to increase the 
stability of the natural compounds under physiological conditions. Following these 
strategy of coordinating a metal centre with natural compounds with therapeutic 
properties, there are a few literature reports on coordination of metal ions with 
curcumin.103–109 One of the main advantages of this coordination is the stabilisation 
of curcumin - an important issue when considering its potential application in 
medicine. The protocol used to prepare almost all of these metal complexes involves 
a first step of deprotonation of curcumin, thereby stabilising it in the enol form.110 In 
a second step, it is made react, in appropriate molar ratio, with metal halogenates, 
namely of zinc(II), iron(II), nickel(II), copper(II) and ruthenium(II). Regarding 
coordination of the curcumin with ruthenium metal, the published reports focus 
mainly on ruthenium(II) organometallic complexes with curcumin (Figure 5). These 
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complexes were studied and their cytotoxic activity evaluated against several cell 
lines but without being particular light irradiation. 
 
 
Figure 5 – Synthesis of [Ruthenium(II)(R)(curcumin)X] complexes already tested in several 
human tumour and non-tumour cell lines. Where, R=p-cymene, benzene or hexamethylbenzene 
and X=Cl or PTA. i) NaOCH3, MeOH 
 
The preparation of [Ru(II)(p-cymene)(curcumin)Cl] was described in 2012 by 
two different research teams in Italy.104,105 Caruso and co-workers104 studied the 
cytotoxicity of this complex, at 72 h of incubation, against the human tumour cell 
lines: breast (MCF7), colon-rectal (HCT116), ovarian (A2780), ovarian platinum-
resistant (A2780cisR),  lung (A549) and glioblastoma (U87) and compared them 
with that of cisplatin. Their results demonstrated that the complex has greater effect 
in the HCT116 cell line, with an IC50 of 14 mM, followed by MCF7 (20 mM), A2780 
(24 mM) and A2780cisR (27 mM) cell lines; U87 (30 mM) and A549 (65 mM) were 
less sensitive. The effects of the complex on the four most sensitive cell lines tested 
(HCT116, MCF7, A2780 and CP9) were compared to those of cisplatin that were 
still significantly more potent against these cell lines than the [Ru(II)(p-
cymene)(curcumin)Cl] complex as shown in Table 2.  
On the other hand, the group of Bonfili and co-workers105 studied the same 
curcumin complex [Ru(II)(p-cymene)(curcumin)Cl] along with two other 
ruthenium(II) complexes: [Ru(II)(benzene)(curcumin)Cl] and the 
[Ru(II)(hexamethylbenzene)(curcumin)Cl], against the human colorectal cancer 
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HCT116 cell line. The authors pointed out that after 24 h of incubation the complexes 
only exhibited a mild cell growth inhibition (20-30%), which was comparable or lower 
than the found for pure curcumin. The DNA binding ability of the complexes and 
their ability to regulate the activity of the proteasome were also studied. Complexes 
with p-cymene and benzene had shown greater DNA binding affinity than 
hexamethylbenzene complex and pure curcumin. The p-cymene complex also 
showed to be the most potent in inhibiting proteasome in comparison with other 
compounds and pro-apoptotic events were observed, thus representing a potentially 
new, nontoxic and effective compound in cancer therapy.   
More recently, Pettinari and their collaborators studied the synthesis and 
biological activity of new ruthenium(II) complexes: the [Ru(II)(p-
cymene)(curcumin)PTA] and the [Ru(II)(hexamethylbenzene)(curcumin)PTA].106 
The cytotoxicity of this complexes was evaluated at 72 h of incubation against 
ovarian cancer cell lines with and without cisplatinum resistance (A2780cisR and 
A2780 cell lines, respectively), as well as on a non-tumour human embryonic kidney 
cell line, HEK293. Cisplatin was used as reference drug, once it is used in the clinic 
to treat ovarian cancer. The results showed that the prepared complexes possess 
high anti-tumoural activity, inhibiting tumour growth at lower concentrations than the 
reference cisplatin. In general, the new complexes are much more selective towards 
the tumoural cell lines (with marginal activity towards the healthy cell line), unlike 
cisplatin. Besides the excellent cytotoxic results, these authors demonstrated that 
the solubility in water of the novel complex is exceeding cisplatin. All these findings 
are summarised in Table 2. 
Collectively, these results demonstrate that the coordination of curcumin with 
various precursors of Ru(II) is the starting point for the development of new 
anticancer drugs. That is, the coordination of curcumin with the Ru(II) metal centre 
may increase in some cases their selectivity in respect to the action on tumour cells.  
In general, these studies also show that metal complexes of Ru(II) further 
improve the stability of curcumin in solution and under light, and therefore can be 
suited for phototherapeutic application. Furthermore, such complexes could allow 
the study of cellular localization due to curcumin stabilization in vitro. 
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Table 2 – Cytotoxic activities of curcumin and [Ru(II)(R)(curcumin)X] complexes described in 
literature, where R= p-cymene, benzene or hexamethylbenzene and X= Cl or PTA. IC50 values 
of complexes in human cell lines. Cisplatin was tested as a positive control. 
Complex Cell line 
IC50 (mM) 
mean ± SD 
Reference 
[Ru(II)(p-cymene)(curcumin)Cl] 
MCF7 19.58 ± 2.36 104 
HCT116 
13.98 ± 1.50 104 
N/A 105 
A2780 23.38 ± 3.33 104 
A2780cisR 27.00 ± 2.33 104 
A549 62.33 ± 8.93 104 
U87 29.36 ± 1.84 104 
[Ru(II)(benzene)(Cl)(curcumin)Cl] HCT116 N/A 105 
[Ru(II)(hexamethylbenzene)(curcumin)Cl] HCT116 N/A 105 
[Ru(II)(hexamethylbenzene)(curcumin)(PTA)] 
A2780 0.39 ± 0.16 106 
A2780cisR 0.36 ± 0.02 106 
HEK293 4.5 ± 0.5 106 
[Ru(II)(p-cymene)(curcumin)(PTA)] 
A2780 0.39 ± 0.01 106 
A2780cisR 0.40 ± 0.02 106 
HEK293 9.1 ± 1.1 106 
Cisplatin 
MCF7 1.835 ± 0.237 104 
HCT116 5.217 ± 0.348 104 
A2780 
1.325 ± 0.196 104 
1.5 ± 0.2 106 
A2780cisR 
25 ± 3 106 
9.92 ± 1.16 104 
HEK293 7.3 ± 0.6 106 
N/A - not applicable. List of abbreviations on pages xvi-xix. 
 
1.3. Metal complexes in cancer treatment 
The majority of the compounds used in cancer treatment are organic 
molecules, mainly with origin in natural resources, such as plants, microorganisms 
and marine sources.111 However, the optimisation of their large scale synthesis and 
their obtaining in large amount from natural resources can be problematic.112 These 
factors limit their therapeutic use in chemotherapy and increase dramatically their 
costs.  
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Metal complexes, including platinum, gallium and ruthenium have properties 
that make them promising for the development of anticancer drugs.113,114 These 
complexes offer new structural opportunities based on their wide spectrum of 
coordination numbers and geometries,111,115,116 as well as accessible redox 
states115,116 and thermodynamic and kinetic characteristics.111 
 
1.3.1. Platinum complexes 
Cisplatin is, to date, the most successful metal complex used in the treatment 
of cancer. After the discovery of cisplatin by Rosenberg et al.117 in 1965 and its 
extensive application as anticancer drug, numerous platinum compounds have 
been synthesised. Cisplatin, carboplatin and oxaliplatin are approved platinum 
anticancer drugs by FDA that are used in clinic world-wide (Figure 6).  
 
 
Figure 6 - Platinum complexes approved worldwide for clinical use. 
 
The mode of action of cisplatin is well studied. Depending on the cell type 
and concentration, it may induce cytotoxicity by interfering with DNA transcription, 
replication, or both.118–121 It is known that after entering the cell cisplatin is 
hydrolysed and its metal centre platinum(II) binds irreversibly to DNA, causing a 
significant distortion in its structure which brings replication inhibition. Currently, 
cisplatin is used alone or in combination with other drugs; however, it has a high 
toxicity leading to undesirable side effects (for instance, neurotoxicity, nausea and 
vomiting).121 It is inactive against metastasis and some cancers have intrinsic 
resistance and others acquire resistance during treatment.122 When cells become 
resistant to cisplatin, the doses have to be increased, but this can lead to severe 
multi-organ toxicity.123 To minimise cisplatin resistance, alternative therapies have 
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been developed and have proven more effective in defeating cancer than cisplatin, 
namely by use of other metal complexes.124  
 
1.3.2. Ruthenium complexes 
During the past 20 years, ruthenium complexes have captivated a great 
interest as many of them were found be potential new therapeutic agents. Some of 
these complexes have demonstrated, in addition to in vitro cytotoxicity, a relevant in 
vivo anticancer action.125–127 This interest stems mainly from a number of key 
features that make them excellent candidates for drugs, such as: an extensive 
background on the chemistry coordination of ruthenium, the kinetic stability of 
ruthenium in several different oxidation states, the ability of ruthenium to mimic iron 
in binding to human serum proteins (e.g. albumin and transferrin), the octahedral 
geometry which that the structural diversity and a wide range of oxidation states, 
which are accessible chemically and electrochemically (+2, +3 and +4) under 
physiological conditions, allowing their application as redox agents.128–130 Like 
cisplatin, some ruthenium complexes have the ability to bind DNA but faster and 
with more stable bonding.128 This is due to the octahedral geometry that, unlike the 
planar geometry of platinum derivatives, offers no obstacle to binding to DNA. 
Furthermore, it is believed that the ruthenium complex is able to induce cell death 
in tumour cells by either binding to proteins found on the cell surface or interacting 
with mitochondria.131 
Several ruthenium complexes (II or III) have been developed and studied for 
their antiproliferative activity against several cancer cell lines. The New Antitumour 
Metastasis Inhibitor A (NAMI-A) and the trans-[tetrachlorobis(1H-
indazole)ruthenate(III)] (KP1019) were the first ruthenium complexes to enter in 
clinical trials (Figure 7). These complexes are structurally similar to each other, but 
exhibit a different cytotoxic profile and are particularly useful for the treatment of 
metastatic tumours or cisplatin-resistant tumours. 
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Figure 7 – Ruthenium (III) based anticancer complexes NAMI-A and KP1019 in clinical trials 
 
1.3.2.1. Ru(II)-trithiacyclononane complexes 
Recent research largely illustrates that the in vitro and in vivo properties of 
ruthenium compounds can be fine tuned by ligand variation. Several ligands have 
been studied, such as arene (the most studied), the aromatic heterocycles and 
others. The crown thioether 1,4,7- trithiacyclononane ([9]aneS3) (Figure 8) forms 
stable octahedral complexes with several middle and late metal transition elements, 
namely ruthenium, coordinated in a facial manner.132 
 
 
Figure 8 - Structure of macrocyclic ligand 1,4,7-trithiacyclononane ([9]aneS3). 
 
In 2005, it was demonstrated that the arene fragment is not essential for the 
activity of Ru(II) compounds and that it could be replaced by another ligand, such 
as [9]aneS3.133 These macrocyclic type ligands are very attractive due to their  high 
polarity that increases their water solubility and gives good structural stability and 
strong bonding to the metal, helping to stabilise the formed complex and to make it 
relatively inert to the inactivating by biomolecules.134 This typical feature is named 
the macrocyclic effect. They are also known to stabilise the lower oxidation states 
of metal ions.  
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In recent years, a series of new derivatives of the family Ru(II)([9]aneS3) 
complexes have been synthesised and tested for their ability to intercalate with 
DNA.135,136 An example of these precursors is [Ru(II)([9]aneS3)(S-DMSO)Cl2] , 
synthesized by Landgrafe and Sheldrick in 1994 (Figure 9).137 
 
Figure 9 - Molecular structure of [Ru(II)(9aneS3)(S-DMSO)Cl2]. 
 
1.4. Cancer 
Cancer is a general term used for a large number of diseases that are 
characterized by abnormal and uncontrolled cell growth and proliferation.138 The 
initiation and progression of this disease results from the progressive accumulation 
of genetic and epigenetic changes.139,140 Damages in the genetic information can 
be enhanced by environmental factors, including exposure to ionising radiation 
and/or chemical mutagenic agents.141 The changes lead to cell cycle arrest and 
increased function of proteins that activate cell proliferation, in particular growth 
factors and their receptors, anti-apoptotic proteins and transcription factors. These 
proteins are thus important targets for tumour treatment.138  
Chemotherapy, radiotherapy and surgery, either alone or in combination, are 
the most commonly applied techniques in cancer therapy.142 The choice of the 
technique to be used depends on several factors: the location, the type and the size 
of the primary tumour and the presence or absence of metastasis. Chemotherapy 
can be neoadjuvant (before surgery to reduce the tumour size) or adjuvant (after 
surgery to eliminate the remaining microscopic metastases). However, 
chemotherapeutic compounds and radiation affect the healthy adjacent tissues, 
which poses restrictions to their effective use.143 It is thus relevant to improve the 
existing oncological therapies or to develop new forms of treatment based on new 
approaches. 
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1.5. Prostate cancer 
Prostate cancer (PCa) is a common urologic malignancy in men and the 
second leading cause of death from cancer in United States of America (USA) and 
in European countries.144 The incidence of PCa in Asian countries is much lower 
compared to the USA, which may be related to the fact that Asian population 
consumes large amounts of fruits, vegetables and non-processed food.145,146 
Although the mechanisms involved in the development of this disease are not yet 
fully defined, is has been associated with the presence of some risk factors: old age, 
ethnicity, family history of PCa and hormonal alterations.147 Several reports have 
described that more than 65% of all PCa are diagnosed in men over 65 years old148 
and that the incidence of PCa is 60% higher in black population compared to 
Caucasians. Besides, environmental factors, such as eating habits, exposure to 
chemicals and sexually transmitted infections have also been associated with the 
pathology. 
PCa occurs as two forms: (i) localized (confined to the prostate gland) and 
androgen-dependent; (ii) metastatic and androgen-independent.149 In the early 
stages of the disease, the growth of PCa cells are androgen-dependent and thus 
confined to the prostate gland. However, PCa cells often become hormone 
refractory (androgen-independent).150 This progression step is followed by 
metastasis formation. Several molecular mechanisms are involved in PCa’s 
propensity to metastasise. These mechanisms lead to local invasion, migration and 
site-specific establishment of metastases at secondary sites, such as bone, lung 
and liver.151 PCa differs from other types of cancer by the late onset of the first 
symptoms and slow evolution. Often, the manifestation of the first symptoms, 
including difficulty in urinating, the presence of blood in the urine and pain or burning 
when urinating occurs in an advanced stage of the disease.152  
Presently, the first approach to the diagnosis of PCa is performed by digital 
rectal examination (DRE), blood test for a tumour biomarker known as prostate-
specific antigen (PSA), and transrectal ultrasonography (TRUS).153,154 PSA is a 
serine protease extensively used for risk stratification of prostate cancer, which 
enables the early detection of the malignancy with possible decrease in the number 
of deaths.155 Usually, a high total PSA (tPSA) value (> 4 ng/mL) in the patient's blood 
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indicates the presence of disease, since the tumour cells of prostate cancer tend to 
increase the production of PSA. However, PSA has also been found in human 
normal cells and its seric levels may be increased due to other conditions of the 
prostate, such as infection, irritation, benign prostatic hypertrophy, recent 
ejaculation, or medical interventions.153,156–159 For a definitive diagnosis it is 
essential to conduct a biopsy on the prostate. 
Treatment of prostate cancer should be selected according to the grade and 
stage of the tumour, the tPSA levels and the estimated lifetime of the patient.160 
Localised tumours can be efficiently treated by radical prostatectomy, radiotherapy 
and hormone therapy (androgen deprivation).161 The androgen-deprivation therapy 
(ADT), which suppresses or reduces androgens binding to the androgen receptor 
(AR), is a well-known treatment strategy for early stages of PCa, since cells will not 
grow and survive without androgens.162 Metastatic PCa, however, poses major 
therapeutic challenges: it initially responds well to androgen-deprivation therapies, 
but the majority of tumours evolves from an androgen-sensitive to an androgen-
independent form of the disease, also known as castration-resistant prostate 
cancer, and often metastasise and bringing a poor prognosis.163 Since the existing 
therapies for PCa are not effective for major types of cancers, chemoprevention is 
emerging as an attractive additional strategy for disease control.164 Several 
molecular pathways of PCa could be the targets for chemoprevention (Table 3).  
Naturally occurring cancer chemopreventive agents include the curcumin that 
modulates numerous potential targets for PCa chemoprevention. Curcumin inhibits 
PCa cell viability, proliferation and migration.165 It has been reported to inhibit the 
NF-kB activation in PC-3 cell line.68 Moreover, curcumin has the ability to induce 
apoptosis in both androgen-dependent (PC-3) and androgen-independent (LNCaP) 
PCa cells, downregulating apoptosis suppressor proteins, AR and co-factors,166 and 
MMP (MMP-2 and MMP-9) activity, important prerequisites to tumor invasion and 
metastasis of PCa cells.167 
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Table 3 - Potential targets for prostate cancer chemoprevention.  
Molecular events Molecular target 
Signalling pathways 
AR 
EGFR 
IGFR 
STAT-3 
Cell cycle 
CDK-cyclin 
Telomerase 
Cell survival/apoptosis 
NF-kB 
Bcl-2 
Angiogenesis/metastasis 
VEGF 
MMP 
List of abbreviations on pages xvi-xix. 
 
1.6. Photodynamic therapy in cancer treatment  
As indicated above, cancer therapy includes surgery, chemotherapy, 
radiotherapy and more recently, immunotherapy. However, these techniques can 
cause some physical damage in healthy tissues of patients.168 Therefore, it is crucial 
to develop of therapeutic approaches that allow eradication of tumour with minor 
damages to patients. A promising strategy is photodynamic therapy (PDT) a 
minimally invasive and selective technique for the treatment of various cancers, and 
for the inactivation of bacteria, virus and other microbes.169–172 Moreover, PDT has 
is approved as therapeutics for psoriasis, acne, actinic keratosis and wet age-
macular degeneration.173,174 
PDT has three key players: light, photosensitizer (PS) and oxygen. PDT is a 
two-step procedure: first, a drug is administered to the organism and next the target 
tissue is irradiated.169 It uses a specific wavelength light laser or led that activates 
the PS and produces highly reactive specie of oxygen (e.g. singlet oxygen), which 
results in destruction of tumour cells. The same PS excited by different range of 
wavelengths produces different generation rates of single oxygen that can be 
effective against different diseases.175 PDT relies on two different mechanisms: 
Type I and Type II.176 In Type I, the PS on the triplet excited state reacts with a 
substrate and transfer an electron or proton. This leads to the formation of radicals 
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that can interact with molecular oxygen and form reactive oxygen species (ROS), 
such as superoxide, hydroxyl radical and peroxides. These ROS are highly reactive 
agents that can cause cell death. In the Type II reaction, occur an energy 
transference from the triplet state of the PS to molecular oxygen in its ground triplet 
state (3O2). In this case, singlet oxygen (1O2) is generated.   
 The major advantage of PDT is the fact that the select PS is non-toxic in the 
absence of light (although sometimes there may be a minimal toxicity). In addition, 
it is a localized treatment with low accumulation in non-specific tissues177 and the 
non-ionizing activating light is harmless on the tissues that have no PS drug. 
Because of these characteristics, PDT is recognized as a highly selective form of 
cancer therapy.178  
The most widely used photosensitizer in current clinical use is Photofrin®.179 
This PS is used in the treatment of early and late-stage lung cancers, oesophageal 
cancer, bladder cancer, early stage cervical cancer, and malignant and non-
malignant skin diseases.180,181 However, it has disadvantages including skin 
photosensitivity and a relative small absorbance peak at 630 nm making it 
somewhat inefficient in use, especially for bulky tumours where light penetration is 
problematic.169 
 
1.6.1. Curcumin in photodynamic therapy  
Some studies have proposed that the anticancer activity of curcumin may 
possibly be enhanced by light application and showed that curcumin with PDT is 
effective for inhibiting the growth of epithelial carcinoma cells (A431),182,183 salivary 
gland acinar cells (SM 10-12),184 nasopharyngeal carcinoma cells (CNE1 and 
CNE2),185,186 keratinocyte cancer cells (HaCaT),187,188 breast cancer (MCF-7)189 and 
head and neck cancer cells (AMC-HN3).190 
In 2012, the combined action of PDT and curcumin was studied on AMC-
HN3, results showing 70% cell viability reduction for the combination treatment and 
only 50% or 10% reductions for treatments with, respectively, PDT or curcumin 
alone.190 Moreover, the combination treatment enhanced the apoptotic events (e.g. 
nuclear fragmentation and nuclear condensation). 
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Other study published in 2012 evaluated the photodynamic effect of curcumin 
on planktonic cultures of Streptococus mutans and Lactobacillus acidophilus using 
a blue light emitting diode and curcumin as photosensitizer.191 The results show that 
the group that used curcumin followed by blue light illumination contained a 
significantly lower number of bacteria than did any other group. Moreover, the 
photodynamic effect was dose dependent for the curcumin concentration. The 
authors also tested the same conditions in the dark and observed that, curcumin 
alone for the concentrations tested did not affect the viability of the microorganisms. 
More recently, a group of researchers studied the use of blue light and curcumin for 
elimination of Streptococus mutans.192 The results showed that the combination of 
curcumin and light enhanced the percentage of reduction of viability of 
microorganisms, corroborating the results obtained previously by other authors.  
In general, the results of these all studies suggest that curcumin under PDT 
has a better treatment efficiency in vitro. However, there is no information about 
anticancer effects of curcumin in human prostate cancer cells. 
 
1.7. Aims of this work 
The general purpose of this work is to synthesise and characterise 
ruthenium(II)-trithiacyclononane complexes with a biologically active ligand 
curcumin and evaluate its potential as anticancer agent against prostate cancer 
cells. This was intended to be achieved through a series of steps: 
(i) the isolation and purification of curcumin from turmeric powder; 
(ii) the synthesis of the novel ruthenium(II)-trithiacyclononane complexes with 
curcumin as a ligand; 
(iii) the structural elucidation and physicochemical properties evaluation of the 
novel complexes using adequate characterisation techniques (elemental 
analysis, solution 1H and 13C Nuclear Magnetic Resonance spectroscopies, 
Mass Spectrometry (ESI-MS), UV-Visible spectroscopy solution and 
fluorescence spectroscopy); 
(iv) the study of binding interaction of the complexes and non-complexed 
curcumin with salmon sperm DNA; 
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(v) the evaluation of the cytotoxicity of the complexes towards human prostate 
cells (PNT-2, non-neoplastic and PC-3, neoplastic) in comparison with that of 
non-complexed curcumin in dark and light conditions in order to evaluated PDT 
effects. 
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2. Experimental section 
 
2.1. Equipment  
1H and 13C Nuclear Magnetic Resonance (NMR) spectra were recorded 
on a Bruker Avance 300 spectrometer at 300.13 MHz and 75.47 MHz, 
respectively, at room temperature. Unequivocal 1H and 13C assignments were 
made using 2D correlation spectroscopy (COSY, 1H,1H), while 13C assignments 
were made on the basis of 2D heteronuclear single quantum coherence 
spectroscopy (HSQC, 1H,13C), and heteronuclear multiple bond correlation 
(HMBC, delay for long-range J C/H couplings were optimized for 7 Hz) 
experiments. Deuterated chloroform (CDCl3) was used as solvent (1H 7.26 ppm 
and 13C 77.29, 77.03 and 76.68 ppm) and tetramethylsilane (TMS) as internal 
reference. Chemical shifts are quoted in parts per million (ppm) and the coupling 
constants (J) in Hertz (Hz).  
Mass spectra were recorded in a Micromass® Q-TOF 2 mass spectrometer 
using methanol as solvent and electrospray ionization (ESI-MS). The m/z ratios 
presented in the characterisation data for the sample are monoisotopic, 
calculated using the mass of the most abundant natural isotope of each 
constituent element (1H, 12C, 14N, 16O, 32S, 35Cl and 102Ru).  
Elemental analysis for CHNS was performed in a TruSpec 630-200-200 
CHNS Analyser.  
Ultraviolet-visible (UV-Vis) solution spectra were obtained at 25 ºC using 
1 x 1 cm quartz optical cells and recorded on a Shimadzu UV-2501 PC 
spectrophotometer using dimethylformamide (DMF) or dimethylsulfoxide 
(DMSO) as solvent. Molar absorptivity of each compound were determined using 
Beer’s law.  
Fluorescence spectra were recorded on a spectrofluorimeter Fluoromax 
(Horiba-Jobin-Yvon) at 25 ºC in DMF using 1 x 1 cm quartz fluorescence cells 
under normal air conditions. 
UV-Vis spectra for the DNA interaction experiments (affinity constant 
determination and denaturation temperature assays) were collected using 1 x 1 
cm quartz cells on a GBC Cintra 500 UV-Visible spectrophotometer equipped 
with a temperature controller (GBC Thermocell). For the denaturation 
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temperature assay, the absorbance at 260 nm was measured at different 
temperature values using a heating rate of 0.25 ºC/min over the range 50-99 ºC. 
The optical density (OD) of the microplates was then measured at 540 and 
630 nm using the microplate reader Tecan Infinite® 200 PRO series.  
 
2.2. Materials 
The ruthenium complex [Ru([9]aneS3)(S-DMSO)Cl2] was kindly provided 
by Susana Santos Braga of the University of Aveiro. This complex was the 
ruthenium(II) precursor used in this work and was synthesized according to the 
optimization of the method of Landgrafe and Sheldrick137 published by Madureira 
et al.136 5,10,15,20-Tetraphenylporphyrin (TPP), kindly provide by Maria do 
Amparo Faustino of the University of Aveiro, was used as reference in some 
studies of this work, such as fluorescence quantum yield and singlet oxygen 
measurements. 
Distilled acetone was used for the extraction of curcuminoids from the 
turmeric powder, while distilled dichloromethane was used for the subsequent 
isolation of curcumin by column chromatography (CC). Hexane (≥ 99.0%), diethyl 
ether (≥ 99.8%), sodium methoxide (95.0%) and deoxyribonucleic acid low 
molecular weight from salmon sperm were supplied by Sigma-Aldrich (Sintra, 
Portugal) and were used without further purification. Chloroform (≥ 99.8%) was 
purchased from Merck (Darmstadt, Germany). Methanol, used in the synthesis 
of the new complex, was supplied by Fisher Scientific (Porto Salvo, Portugal). 
Phosphate buffered saline (PBS, 10x) Dulbecco’s formula used for preparation 
of solutions for DNA binding studies, was purchased from Alfa Aesar (Karlsruche, 
Germany). 
Roswell Park Memorial Institute (RPMI)-1640 medium was acquired from 
Gibco, Invitrogen (New York, USA). FBS, penicillin/streptomycin and trypsin-
EDTA were purchased from Hyclone (Utah, USA). AlamarBlue (AB) and Trypan 
Blue (TB) were obtained from ThermoFisher (Massachusetts, USA). 
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2.3. Methods 
 
2.3.1. Extraction and isolation of curcumin 
 
2.3.1.1. Extraction of curcuminoids 
Fifteen grams of turmeric powder were dissolved in distilled acetone and 
magnetically stirred for 4 h at room temperature. The mixture was decanted and 
concentrated in a rotary evaporator at 40 ºC. Thin layer chromatography (TLC) 
analysis of the crude extract using 99:1 – dichloromethane:methanol as eluent 
showed the presence of three major components: curcumin, 
desmethoxycurcumin and bisdesmethoxycurcumin.  
 
2.3.1.2. Isolation of curcumin 
The crude material obtained after extraction with acetone was dissolved in 
99:1 – dichloromethane:methanol, mixed with a small amount of silica gel (60-
120 mesh), introduced in the top of a glass column packed with silica and 
subjected to CC. The first eluent used was dichloromethane, followed by 99:1 
(V/V) dichloromethane/methanol mixture to yield pure fractions of curcumin.22 A 
suitable mobile phase to elute the compounds was chosen by determination of 
Rf values on TLC plates with UV-detection. The presence of curcumin on the 
major fraction collected was verified using TLC (Rf values: 0.49, 0.32, and 0.21 
for curcumin, desmethoxycurcumin and bisdesmethoxycurcumin, respectively) 
and NMR analysis. The saffron yellow curcumin was re-dissolved in a small 
amount of chloroform and crystalized from a mixture of chloroform/hexane. 
 
 
 
1H NMR (300.13 MHz, CDCl3): δ (ppm) = 16.07 (1H, s, 2’-OH), 7.60 (2H, d, J= 
15.8 Hz, H-4,4’), 7.13 (2H, dd, J= 8.2 Hz, J= 1.9 Hz, H-10,10’), 7.06 (2H, d, J= 
1.9 Hz, H-6,6’), 6.94 (2H, d, J= 8.2 Hz, H-9,9’), 6.48 (2H, d, J= 15.8 Hz, H-3,3’), 
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5.86 (2H, s, 8,8’-OH), 5.80 (1H, s, H-1), 3.95 (6H, s, 7,7’-OCH3). 
13C NMR (75.47 MHz, CDCl3): δ (ppm) = 183.5 (C-2,2’), 148.0 (C-8,8’), 146.8 (C-
7,7’), 140.5 (C-4,4’), 127.8 (C-5,5’), 123.1 (C-3,3’), 121.9 (C-10,10’), 115.8 (C-
9,9’), 114.8 (C-6,6’), 109.7 (C-1), 56.0 (7,7’-OCH3).  
UV-Vis (DMF): λmax (log ε) = 430 nm (104.70). UV-Vis (DMSO): λmax (log ε) = 435 
nm (104.68) 
 
2.3.2. Preparation of [Ru([9]aneS3)(curcumin)(S-DMSO)]Cl 
complex (Ru-curc complex) 
A solution of curcumin (67.0 mg, 0.182 mmol) in 20 mL of methanol was 
treated with sodium methoxide (9.83 mg, 0.182 mmol), and it was observed the 
solution colour changed from saffron yellow to dark red. The mixture was stirred 
and heated at 68 ºC for 30 min under a nitrogen atmosphere. Then, 
[Ru([9]aneS3)(S-DMSO)Cl2] (62.5 mg, 0.182 mmol) dissolved in methanol (20 
mL) was added and the mixture was refluxed for 24h at 68 ºC under stir. The 
reactional mixture was allowed to cool for 30 min, after which the methanol was 
evaporated on a rotary evaporator to near dryness (~2 mL methanol). It was then 
added diethyl ether (~5 mL) and the solution was kept in the refrigerator for three 
days to obtain a microcrystalline dark red precipitate. The precipitate was isolated 
by filtering (using Willstätter nail), washed with diethyl ether (~15 mL), and dried 
(49.1 mg, 37 % yield).  
 
Elemental analysis for [Ru(C6H12S3)(C21H19O6)(C2H6SO)]Cl·(NaCl) (Mr = 
785.01) calculated: C, 40.33; H, 4.80; S, 16.30. Found: C, 39.97; H, 4.90; S, 
15.30;  
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ESI+-MS m/z (relative intensity %): 727 ([Ru([9]aneS3)(curc)(S-DMSO)]+, 100); 
621 ([Ru([9]aneS3–CH2CH2)(curc)]+, 56).  
1H NMR (300.13 MHz, CDCl3): δ(ppm) = 7.30 (2H, d, J= 16.7 Hz, H-4,4’), 7.10 
(2H, dd, J= 1.8 Hz, J= 8.3 Hz, H-10,10’), 7.01 (2H, d, J= 1.8 Hz, H-6,6’), 6.94 (2H, 
d, J= 8.3 Hz, H-9,9’), 6.49 (2H, d, J= 16.7 Hz, H-3,3’), 5.64 (1H, s, H-1) 3.96 (6H, 
s, 7,7’-OCH3), 2.96 (6H, s, S-CH3), 3.66-3.58, 3.42-3.38, 2.93-2.80, 2.72-2.65 
(12H, m, CH2-[9]aneS3) 
13C NMR (75.47 MHz, CDCl3): δ(ppm) = 178.3 (C-2,2’), 148.6 (C-8,8’), 147.5 (C-
7,7’), 138.0 (C-4,4’), 129.2 (C-5,5’), 124.5 (C-3,3’), 121.9 (C-10,10’), 115.4 (C-
9,9’), 110.4 (C-6,6’), 102.2 (C-1), 55.1 (7,7’-OCH3), 42.2 (S-CH3), 33.6, 32.1, 29.5 
(CH2-[9]aneS3). 
UV-Vis (DMF): λmax (log ε) = 412 nm (4.51). UV-Vis (DMSO): λmax (log ε) = 405 
nm (4.39) 
 
2.3.3. Fluorescence quantum yield 
The fluorescence quantum yields (ΦF) of curcumin and Ru-curc complex 
were calculated by comparison of the area below the corrected emission 
spectrum with that of TPP. TPP was used as fluorescence standard (λexc = 430 
nm) with ΦF = 0.12 in DMF.193 In all cases, the absorbance (Abs) of the sample 
and reference solutions was kept at 0.02 at the 430 nm (the excitation 
wavelength). Fluorescence quantum yield was calculated according to the 
equation: 
ΦF
sample
=ΦF
reference AUC
sample(1-10-Abssample)
AUC
reference(1-10-Absreference)
 
 
where, AUC is the integrated area under the fluorescence curves of each 
sample and the reference and Abs is the absorbance of the samples and the 
reference at the excitation wavelength (430 nm).  
 
 
2.3.4. Singlet oxygen measurements 
The quantum yield for singlet oxygen generation (ΦΔ) upon excitation was 
evaluated in N,N-dimethylformamide (DMF) by a photooxidation method using 
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9,10-dimethylanthracene (DMA) as 1O2-sensitive indicator. This process is based 
on the quenching of DMA by 1O2, exclusively in the chemical reaction and yielding 
9,10-dimethyl-9,10-dihydro-9,10-epidioxyanthracene (Figure 10).194,195 
 
 
Figure 10 - Photobleaching reaction of 9,10-dimethylanthracene by 1O2 
 
The kinetics of DMA photooxidation was studied by following the decrease 
in its Abs at λ=378 nm. Solutions of 9,10-dimethylanthracene (DMA; 30 μM) and 
curcumin or Ru-curc (λ=430 nm; Abs=0.1) in DMF (2.5 mL) were  irradiated in 
quartz cuvettes with monochromatic light at 430 nm obtained through a band-
pass filter at an irradiance of 30.0 mW/cm2. TPP was used as reference (ΦΔ= 
0.62).196 Measurements of the samples and reference under the same conditions 
afforded ΦΔ by direct comparison of the slopes in the linear region of the 
plots. The observed rate constants (Kobs) were obtained by a linear least-squares 
fit of semi-logarithmic plots of ln(A0/A) versus time for DMA.  
 
2.3.5. DNA binding studies 
In this work, the DNA binding studies were performed using 
deoxyribonucleic acid of salmon sperm (sp-DNA). The solution of sp-DNA in 
phosphate buffered saline (PBS) gave an absorbance ratio at 260 and 280 nm of 
about 1.81, indicating that the sp-DNA was free of protein. The final concentration 
of sp-DNA was determined spectrophotometrically by employing an extinction 
coefficient of 6600 M-1 cm-1 at 260 nm. Stock solutions were stored at 4ºC and 
used over no more than 2 days. 
 
2.3.5.1. Determination of the DNA affinity constant  
Concentrated stock solutions of free curcumin or Ru-curc complex were 
prepared by dissolving the compounds in 1% DMSO buffer and diluting suitably 
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with the buffer to the required concentrations for all the experiments. The binding 
propensity of the compounds to sp-DNA was evaluated using spectral methods. 
UV-Vis spectra of sp-DNA and tested compounds at various concentrations of 
sp-DNA were measured from 200 to 900 nm in PBS. The absorbance 
measurements were performed by keeping the free curcumin or complex 
solutions concentration constant (30 μM) while varying the DNA concentration 
from 0 to 100 μM (rj = [DNA]/[compound] = 0-3.3). This was achieved by diluting 
an appropriate amount of the curcumin or complex and sp-DNA stock solutions 
in PBS while maintaining the total volume constant (3.0 mL).  
The intrinsic binding constant (Kb) was calculated according to the 
following equation: 
[DNA]
(εa-εf)
= 
[DNA]
(εb-εf)
+ 
1
Kb(εb-εf)
 
 
where, [DNA] is the concentration of DNA. εa correspond to the apparent 
extinction coefficient of the tested compounds and is calculated by [compound 
tested]/Absmáx. εf is the extinction coefficient for free compound in the solvent 
used for the preparation of solutions; εb is entirely DNA-bound combination. When 
plotting [DNA]/(εa − εf) versus [DNA], one obtains a linear plot. The slope of the 
plot corresponds of 1/(εb − εf), allowing then to obtain Kb. 
 
2.3.5.2. DNA denaturation temperature assay 
The thermal denaturation of curcumin/sp-DNA and Ru-curc/sp-DNA 
mixtures (1:10) was determined in a 10 mM PBS (pH 7.2) solution prepared with 
ultra-pure water.  Melting curves were recorded by heating the mixtures in steps 
of 5 ºC. For each temperature point, absorbance readings were collected at the 
wavelength of 260 nm and the experiments occurred in triplicate. The melting 
temperatures (Tm) of the native and modified sp-DNA were calculated by 
determining the midpoints of the melting curves from the first-order derivatives. 
Experimental ΔTm values were estimated to be accurate within ±1 °C.  
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2.3.6. Biological assays  
 
2.3.6.1.Cell culture 
In this study, two human prostate cell lines were used: PNT-2 (non-
neoplastic cell line), kindly given by Dr. Ricardo Perez-Tomás (University of 
Barcelona, Spain) and PC-3 (neoplastic cell line androgen-independent), kindly 
given by Dr. Rui Medeiros (University of Porto, Portugal). Cells were cultured in 
RPMI-1640, supplemented with 10% FBS and 1% penicillin/streptomycin 
mixture, and maintained in a humidified atmosphere at 37ºC containing 5% CO2. 
Cells having a narrow range of passage number were used for all experiments. 
 
2.3.6.2. Cell viability assay 
Cell viability was evaluated using the AB assay. AB, also known resasurin, 
is a water-soluble dye that has been used for quantifying the viability of various 
cells.197,198 It allows a continuous monitoring of cultures over time due to the fact 
that it is extremely stable and nontoxic to cells.198 When added to cell cultures, 
the oxidized form of the AB enters the cytosol and is converted to the reduced 
form by mitochondrial enzyme activity by accepting electrons from NADPH, 
FADH, FMNH, NADH, as well as from the cytochromes. This redox reaction is 
accompanied by a shift in color of the culture medium from indigo blue to 
fluorescent pink, which can be easily measured by colorimetric or fluorescence 
reading.199 The number of viable cells correlates with the magnitude of the 
reduction of the dye and it is expressed as percentage of AB reduction.198 The 
assay was developed according to the manufacturer’s instructions and the 
percentage of AB reduction (%AB reduction) was calculated as follows: 
 
%𝐴𝐵 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =  
(𝜀𝑜𝑥𝜆2)(𝐴𝜆1) − (𝜀𝑜𝑥𝜆1)(𝐴𝜆2)
(𝜀𝑟𝑒𝑑𝜆1)(𝐴′𝜆2) − (𝜀𝑟𝑒𝑑𝜆2)(𝐴′𝜆1)
× 100 
 
where, ελ1 and ελ2 are constants representing the molar extinction 
coefficient of AB at 540 and 630 nm which represent the oxidized (εox) and 
reduced (εred) forms, respectively: Aλ1 and Aλ2 represent absorbance of test wells 
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at 540 and 630 nm, respectively, and A’λ1 and A’λ2 represent absorbance of 
negative control at 540 and 630 nm, respectively. 
Cells from confluent 100 mm plate were harvested with trypsin and 
counted with TB in a hemocytometer. Different cells densities (500, 1250, 2500, 
5000, 10000, 20000 and 40000 cells per well) were seeded into duplicate wells 
of a 96-well plate (100 μL per well). Then, 10 μL AB solution were directly added 
to the medium. RPMI with 10% AB was used as blank. The plate was further 
incubated at 37 ºC. The absorbance of test and control wells was read at 1, 2, 4, 
6, 8 and 24 h after adding AB at 540 and 630 nm with a plate reader.  
 
2.3.6.3. Preparation of stock solutions of the compounds 
Fresh stock solutions were prepared in DMSO and protected from light. 
Further dilutions of these stock solutions were made in RPMI-1640, keeping only 
1% of DMSO, in order to obtain the final concentrations required for the biological 
assays. In all the experiments, for both control and treated samples, the highest 
concentration of DMSO used in each well was 1% (v/v). 
 
2.3.6.4. Cytotoxic assay 
The cytotoxicity of curcumin and Ru-curc complex was determined using 
the AB assay. Cells were seeded (5000 cells per well) in 96-well plates (100 μL 
per well) and incubated at 37 ºC for 24 h to let cells adhere. Different 
concentrations (80, 50 and 20 μM) of the test compounds were then added and 
plate was further incubated at 37 ºC. After 48 h the medium was removed and 
changed to fresh medium and the 96-well plates were further incubated for more 
24 h. Sixteen hours before the endpoint of the experiment, 10 μL of AB solution 
were added to each well. RPMI with 10 % AB was used as blank, whereas cells 
without treatment and cells treated with 1% DMSO were used as controls. For 
each condition, including the control conditions, three replicates were prepared 
and the experiments prepared in triplicate.  
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2.3.6.5. Phototoxic assay 
The phototoxic potential of curcumin and Ru-curc complex was 
determined using the AB assay. Cells were seeded (5000 cells per well) in two 
96-well plates (100 μL per well) and incubated at 37 ºC for 24 h to let cells adhere. 
Different concentrations (80, 50 and 20 μM) of the test compounds were then 
added and the plate was further incubated at 37 ºC. After 48 h of incubation with 
compounds, plates were irradiated with white light (10 mW/cm2) for 10 min. After 
illumination, the medium was removed and changed to fresh medium and the 
plates were incubated for 24 h. Sixteen hours before the endpoint of the 
experiment, 10 μL of AB solution was added to each well. RPMI with 10% AB 
was used as blank, whereas cells without treatment and cells treated with 1% 
DMSO were used as controls. For each condition, including the control 
conditions, three replicates were prepared and the three independent 
experiments were done in separate days.  
 
2.3.7. Statistical analysis 
Statistical analysis of the data from the % AB reduced by cells treated with 
the compounds under study, was carried out using GraphPad Prism 7.01 
software for Windows. The results are expressed as a mean and standard 
deviation obtained from three independent experiments, each comprising three 
replicate measurements performed for each concentration of each compound 
tested plus the untreated control. For all the measurements, one-way ANOVA 
followed by the Dunnett’s post hoc test were used to assess the statistical 
significance between groups. A P-value of <0.05 was considered significant. For 
intra- and inter-assay variability, data from three consecutive experiments were 
analysed.  
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3. Results and discussion 
 
3.1. Extraction and isolation of curcumin 
Curcuminoids are soluble in various organic solvents including ethanol, 
methanol, dichloromethane and acetone.200 Thus, several methods and solvents 
systems were reported in literature for the extraction of curcuminoids from the 
turmeric powder, as indicated above in section 1.Introduction.14 In this work, we 
used acetone as extracting solvent. An amount of 2.19 g of extracted 
curcuminoids were obtained from 15 g of turmeric powder. The confirmation of 
presence of the three curcuminoids in the extract was confirmed by TLC. All the 
three spots showed to be fluorescent under UV light. Several eluent systems 
were studied for separation of curcuminoids by chromatography, but 99:1 (v/v) 
dichloromethane:methanol provided the best results, being thus elected as the 
eluent for the separation of curcuminoids by column chromatography. With this 
eluent, the three main curcuminoids present in the acetone extract showed Rf 
values (in silica gel) of 0.49, 0.32, and 0.21 for curcumin, desmethoxycurcumin 
and bisdesmethoxycurcumin, respectively.  
As indicated in the Introduction, several methods have been reported for 
the isolation of curcumin, such as TLC, CC and HPLC, using different 
combinations of stationary and mobile phases. In this study, we used a wet 
column chromatography. The stationary phase used was silica gel 60-120 mesh 
and for mobile phase was first dichloromethane and then a mixture of 99:1 – 
dichloromethane:methanol. After elution with about 1400 mL, 116 mg (5.3% 
yield) of pure curcumin was obtained and the other two curcuminoids were 
discarded on the column chromatography. The amount of curcuminoids obtained 
is influenced by the curcuminoids content of the turmeric powder, which varies 
from source to source. The solvent in the pure fractions curcumin was evaporated 
at reduced pressure and the residue taken into chloroform (ca. 1 mL) and 
crystallised in hexane, to obtain a saffron yellow solid powder (93 mg) comprising 
pure curcumin. The purity of curcumin was confirmed by 1H and 13C NMR and 
comparing the results with those of the literature and its purity was assessed 
using TLC.22  
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Figure 11 – Carbon labeling scheme for the curcumin 
 
Figure 11 depicts the chemical structure of curcumin with the numbers 
used to identify the carbon resonances in the NMR spectrum. The 1H NMR 
spectrum of curcumin was recorded in CDCl3. This spectrum possesses 
resonance peaks in 3 main areas: in the aliphatic area, a singlet at δ 3.95 ppm 
corresponding to the resonance of 6 protons of the two methoxyl groups (-OCH3) 
(Figure 12 and Table 4); in the most unprotected area at δ 16.07 ppm, a broad 
singlet typical of a OH in hydrogen bridge, which confirms the presence of 
curcumin in the enol form; and finally, in the range δ 5.7 – 7.6 ppm appear the 
peaks due to the resonances of the remaining protons. The values of the 
chemical shifts of all protons and the coupling constants are in agreement with 
the ones reported in the literature.22 
 
 
Figure 12 - 1H NMR spectrum recorded in CDCl3 for the curcumin  
 
The 13C NMR spectrum of curcumin was recorded in CDCl3 (Figure 13 and 
Table 5). The 2D NMR experiments (HMBC and HSQC) allowed the identification 
and confirmation of the carbon resonance assignments. All the chemical shift 
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values obtained were in accordance with the reported resonances in the literature 
for curcumin.22 Thus, we concluded that curcumin obtained from turmeric was in 
pure form and free of the presence of other two pigments.  
 
 
Figure 13 - 13C NMR spectrum recorded in CDCl3 of curcumin. 
 
3.2. Ruthenium(II)-trithiacyclononane complex with curcumin 
The scheme depicted in Figure 14 illustrate the first attempt to synthesise 
a Ru-curc complex. The curcumin hydroxyl group of position 2 was first 
deprotonated using sodium methoxide (1 equivalent), making the curcumin 
solution change from strong saffron yellow to red. After 30 min of reflux to ensure 
full deprotonation, one equivalent of the ruthenium(II) precursor [Ru([9]aneS3)(S-
DMSO)Cl2 was added and the reaction was kept under reflux for another 24 h. 
After the reactional mixture had been cooled down, the solvent was reduced to a 
minimal amount under reduced pressure and the addition of diethyl ether allowed 
the formation of a red precipitate, which was isolated upon filtration, washed and 
dried (49.1 mg, 37.2 % yield). The product showed to be soluble in polar solvents 
as DMSO and methanol, but was insoluble in distilled water.  
 
CDCl3 
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Figure 14 – Reactional scheme for the two-step synthesis of Ru-curc complex. 
 
The structure and purity of the red product isolated was determined by 1H 
and 13C NMR, mass spectrometry and elemental analysis.  
The 1H NMR spectrum of the compound was recorded in CDCl3 (Figure 
15). In this spectrum, the resonances of methylene protons of the thioether 
macrocycle [9]aneS3 appear as 4 multiplets at δ 3.66-3.58, 3.42-3.38, 2.93-2.80 
and 2.72-2.65 ppm. The resonances of protons ascribed to the two equivalent 
methyl groups of coordinated dimethylsulfoxide appear as a singlet at δ 2.96 ppm. 
This feature is an evidence of a S-DMSO coordination. The intensities of the 
resonance signals in the 1H NMR are in agreement with the 1:1 metal-to-curcumin 
stoichiometry proposed.  
Upon the coordination, several changes in the signal resonances of the 
curcumin were observed in the 1H NMR spectrum of the Ru-curc complex (Table 
4). As expected, the resonances of the aromatic rings were not affected, while 
the signal corresponding to the resonance of 2’-OH disappeared, indicating that 
curcumin chelated the ruthenium ion through this group. Moreover, the 
resonances of the H-1 and H-4,4’ were affected and appeared shielded when 
compared with the free curcumin. This effect was a result of the increased 
electronic density. This feature was an evidence of an O,O- coordination. The 
other signals were not significantly affected after coordination as we can see in 
Table 4.  
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Figure 15 - 1H NMR spectrum recorded in CDCl3 of Ru-curc complex. 
  
Table 4- 1H NMR chemical shifts for the ligand curcumin and the Ru-curc complex in CDCl3. 
1H Curcumin Ru-curc complex 
2’-OH 16.07 (s) n/a 
H-4,4’ 7.60 (d), J= 15.8 Hz 7.30 (d), J= 16.7 Hz 
H-10,10’ 
7.13 (dd), J= 8.2 Hz,  
J= 1.9 Hz 
7.10 (dd), J= 8.3 Hz,  
J= 1.8 Hz 
H-6,6’ 7.06 (d), J= 1.9 Hz 7.01 (d), J= 1.8 Hz 
H-9,9’ 6.94 (d), J= 8.2 Hz 6.94 (d), J= 8.3 Hz 
H-3,3’ 6.48 (d), J= 15.8 Hz 6.49 (d), J= 16.7 Hz 
8,8’-OH 5.86 (s) n/o 
H-1 5.80 (s) 5.64 (s) 
-OCH3 3.95 (s) 3.96 (s) 
S-CH3 n/a 2.96 (s) 
CH2-[9]aneS3 n/a 
3.66-3.58 (m),  
3.42-3.38 (m),  
2.93-2.80 (m),  
2.72-2.65 (m) 
Abbreviations used are the following: s – singlet, d – doublet, dd – doublet of doublets, m – 
multiplet, n/a – not applicable and n/o – not observed. 
 
The 2D NMR experiments (HSQC and HMBC) allowed the identification 
and confirmation of the carbon resonances. The 7,7’-OCH3, S-CH3 and CH2-
[9]aneS3 carbons were confirmed by the 1J HSQC correlations, whereas the 2J 
and 3J HMBC correlations allowed the identification of the other carbons.  
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In the 13C NMR spectrum of Ru-curc complex (Figure 16), the resonance 
DMSO methyl groups appeared at 42.2 ppm, whereas the resonance of the six 
methylene carbons of the macrocycle (CH2-[9]aneS3) appeared at 33.6, 32.1 and 
29.5 ppm.  
Several changes in the chemical shifts of the curcumin carbon resonances 
were observed after coordination (Table 5). As expected, the resonances 
ascribed to C-1 and C-2,2’ were the most affected by coordination of curcumin 
with ruthenium, suffering shifts of ca. 8 and 5 ppm, respectively. Furthermore, the 
C-4,4’, C-5,5’ and C-6,6’ signals were also affected and were shielded or 
deshielded, depending on its position. 
 
 
Figure 16 - 13C NMR spectrum recorded in CDCl3 of the Ru-curc complex. 
 
 
The new complex was further analysed by ESI-MS (positive mode). The 
mass spectrum showed two major peaks, the most intense appearing at m/z = 
727 corresponding to [Ru([9]aneS3)(curcumin)(S-DMSO)]+ cation, that is the 
molecular ion. The less intense peak appeared at m/z = 621 and it was attributed 
to the [Ru([9]aneS3–CH2CH2)(curcumin)]+ fragment, due to the loss of one 
ethylene unit of the macrocycle along with DMSO. This confirmed that the 
molecular structure of the synthesized was the compound depicted in the Figure 
14.  
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Table 5 - 13C NMR chemical shifts for the ligand curcumin and the Ru-curc complex. 
13C Curcumin Ru-curc complex 
C-2,2’ 183.5 178.3 
C-8,8’ 148.0 148.6 
C-7,7’ 146.8 147.5 
C-4,4’ 140.5 138.0 
C-5,5’ 127.8 129.2 
C-3,3’ 123.1 124.5 
C-10,10’ 121.9 121.9 
C-9,9’ 115.8 115.4 
C-6,6’ 114.8 110.4 
C-1 109.7 102.2 
7,7’-OCH3 56.0 55.1 
S-CH3 n/a 42.2 
CH2-[9]aneS3 n/a 33.6, 32.1, 29.5 
n/a – not applicable 
 
3.3. Photophysical properties 
 
3.3.1. Absorption spectra 
The absorption properties of curcumin and Ru-curc complex were studied 
in DMF as well as in DMSO. During the preparation of solutions in the two 
solvents we observed that the solvent used altered the colour of solution. The 
UV-Vis spectrum of curcumin and Ru-curc complex recorded in DMF and DMSO 
at 25 ºC are shown in Figure 17.  
The spectrum of the Ru-curc complex exhibited a band in DMF at 413 nm 
and in DMSO at 403 nm, which shifted in comparison with the free curcumin (429 
nm in DMF and 435 nm in DMSO). As shown in Figure 17, the solvent used in 
the preparation of the solutions influenced the maximum absorbance of both 
compounds ligand and complex. These results were consistent with the ones 
observed during the preparation of the solutions.  
Molar absorptivities of curcumin and Ru-curc complex in DMF was 
determined using Beer-Lambert law. The results for molar absorptivity were 
49638 M-1·cm-1 for curcumin and 32448 M-1·cm-1 for Ru-curc complex.  
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Figure 17 – Normalized UV-Vis absorption spectra of curcumin and Ru-curc complex in 
DMF and DMSO at 25 ºC.  
 
The results of this study show that the absorption spectrum of curcumin is 
blue shifted from 429 to 413 nm in DMF after coordination with ruthenium and 
molar absorptivity was also affected. 
 
3.3.2. Fluorescence spectra 
The fluorescence emission spectra of curcumin and Ru-curc complex were 
recorded in DMF (Figure 18) using TPP as reference (ΦF = 0.12).193 All 
compounds with an OD of 0.02 were excited at 430 nm and spectra recorded in 
the range of 450-800 nm. The free curcumin in DMF was able to exhibit 
fluorescence with a quantum yield of fluorescence of 0.18, while the Ru-curc 
complex did not exhibit fluorescence emission after excitation under the same 
conditions. The emission of fluorescence in curcumin is a result of the delocalized 
π-conjugated electronic system and is strongly influenced by solvents, 
tautomerism, and structural modifications.201 This may explain the lack of 
fluorescence in the new complex, since curcumin undergoes a conformational 
change in the keto-enol group. 
Thus, the results showed that curcumin was able to show fluorescence 
emission after excitation, with an emission band around 530 nm, unlike the 
complex that showed no significant fluorescence signals (Figure 18). 
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Figure 18 - Normalized fluorescence emission spectra (λexc 430 nm) of curcumin and Ru-
curc complex in DMF. 
 
3.4. Singlet oxygen studies 
Photooxidation of DMA sensitized by free curcumin and Ru-curc complex 
was studied in DMF (Figure 19). Figure 19 shows typical semi-logarithmic plots 
describing the progress of the reaction of DMA. From first-order kinetic plots of 
the DMA absorption at 378 nm with time the values of the observed rate constant 
(Kobs) were calculated (Table 6). It was observed that no significant 
photodecomposition of DMA (blue circle) was detected in the absence of PS. 
The quantum yield of 1O2 (1Δg) production (ΦΔ) by free curcumin and Ru-
curc complex was calculated using TPP as reference (TPP, Kobs = 1.22x10-3 s-1 
in DMF, ΦΔ = 0.62). The values of ΦΔ for free curcumin (Kobs = 1.18x10-4 s-1 in 
DMF) and Ru-curc complex (Kobs = 8.00x10-5 s-1 in DMF) found were 0.07 and 
0.04, respectively. As can be observed, curcumin and Ru-curc complex 
sensitised the decomposition of DMA in similar rates, indicating no major 
differences in their photoactivities. However, the decomposition rates were quite 
lower than the reference. The results of the photooxidation of DMA in the 
presence of the curcumin or Ru-curc complex showed that they were not good 
singlet oxygen generators, once curcumin has both antioxidant and pro-oxidant 
properties.  
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Figure 19 - First-order plots for the photooxidation of DMA (30 μM) photosensitized by TPP 
(green squares), curcumin (yellow triangles) and Ru-curc complex (grey crosses) in DMF, 
under irradiation at 430 nm at the irradiance of 30 mW/cm2. Values represent mean ± standard 
deviation of three independent experiments. 
 
Table 6 - Kinetic parameters, Kobs (s-1) of the photooxidation reaction of DMA by TPP, 
curcumin and Ru-curc complex after exposure to light of 430 nm at the irradiance of 30 
mW/cm2 and 1O2 quantum yield in DMF.  
Photosensitiser Kobs x 104 (s-1) ΦΔ 
TPP 12.2 0.68 
Curcumin 1.18 0.07 
Ru-curc complex 0.80 0.04 
 
3.5. DNA binding studies 
Small molecules or ligands can interact with DNA double-helix structures 
by three different modes: intercalation, groove binding, or external electrostatic 
binding. However, while groove binding determines only little deviations in the B-
form of DNA double helix, the intercalation mode induces the most dramatic 
changes in the DNA structure.202 Thus, intercalative binding is the most effective 
mode binding for drugs targeted to DNA. The interaction between free curcumin 
or Ru-curc complex and sp-DNA was investigated by UV-Vis absorption 
spectroscopy and DNA melting method. The results of these experiments are 
discussed in the following sub-sections.  
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3.5.1. Absorption spectral studies 
Absorption spectroscopy is an effective method and one of the most useful 
techniques for studying the binding mode of compounds to DNA.203,204 Some 
spectral properties, such as hyperchromism and hypochromism or bathochromic 
and hypsochromic (red or blue shift, respectively) are regarded as characteristic 
of DNA double-helix structural variation during DNA-ligand/complex interactions. 
The hyperchromism on compounds tested means the breakage of the secondary 
structure of DNA; the hypochromism originates from the stabilization of the DNA 
duplex by either the intercalation binding mode or the electrostatic effect of small 
molecules.205 As a rule, complexes that bind to DNA through intercalation result 
in hypochromism along with a bathochromic shift, due to the intercalative mode 
involving a strong stacking interaction between a chromophore and the base pairs 
of DNA.  
The UV-Vis absorption spectra of sp-DNA/curcumin and sp-DNA/ Ru-curc 
complex with various concentrations of sp-DNA in PBS (pH 7.2) at room 
temperature are shown in Figure 20 and Figure 21, respectively. As shown, the 
maximum absorption band of sp-DNA in PBS was around 260 nm. Furthermore, 
the maximum absorption bands of curcumin and Ru-curc complex appeared at 
428 and 403 nm, respectively. These values are in agreement with those 
obtained previously for us in a preliminary study in PBS (data not showed).  
The absorption spectra of the free curcumin upon addition of DNA are 
shown in Figure 20. As shown in this figure, the maximum absorption band of 
curcumin demonstrated a gradual reduction (hypochromism effect) with 
increasing concentration of DNA and a blue shift (hypochromism) was observed 
from 428 to 423 nm. Those spectral modifications can be attributed to the sp-
DNA interaction with the drug, which subsequently affect both the absorbance 
intensity and the absorption band position of curcumin.  
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Figure 20 – UV-Vis absorption spectra of curcumin (30 μM) with increasing concentrations 
of sp-DNA in PBS.  
 
The absorption spectra of the Ru-curc complex upon addition of DNA are 
shown in Figure 21. As shown in Figure 21, the maximum absorption band of Ru-
curc complex in the presence of sp-DNA demonstrated a gradual reduction with 
increasing concentration of DNA and a very weak red shift (bathochromism) was 
observed from 402 to 403 nm. These observations are consistent with the 
intercalation of the complex into the double helix of DNA and provide the evidence 
of the formation of a new complex-DNA adduct. Moreover, this suggests that sp-
DNA might interact with the Ru-curc complex and subsequently affect both the 
absorbance and the absorption band position of the complex. The hypochromic 
effect was observed on the interaction between sp-DNA and Ru-curc complex, 
which constitutes concrete proof of DNA binding to ruthenium metal ion complex.  
 
 
Figure 21 – UV-Vis absorption spectra of Ru-curc complex (30 μM) with increasing 
concentrations of sp-DNA in PBS. 
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The intrinsic binding constant was calculated according to the equation 
indicated in the section 2.3.5. DNA binding studies. The binding constant (Kb) for 
curcumin was 6.75 x 104 M-1 and for Ru-curc complex was 4.00 x 105 M-1. 
Spectroscopic evidence showed that curcumin binds to the major and minor 
grooves of DNA duplex with a binding constant of 5.2 x 104 M-1.206 This value is 
consistent with the one calculated by us. The Kb value obtained for Ru-curc 
complex is similar to those reported for typical classical intercalators. 
 
Table 7 Ligand-based absorption spectral properties and binding constant of compounds 
to sp-DNA. 
Compound 
λmax (nm) 
Binding constant (Kb) (M-1) 
Before titration After titration 
Curcumin 428 423 6.75 x 104 
Ru-curc complex 402 403 4.00 x 105 
 
3.5.2. Thermal denaturation of DNA 
The thermal denaturation experiment is a further evidence for the 
intercalation, or not of compounds into the DNA helix. The DNA melting 
temperature (Tm) is the temperature at which half of the double-stranded DNA is 
dissociated into single strands.207 The intercalation of a drug with DNA can 
stabilize the natural structure of DNA and thus increase the Tm value, whereas 
electrostatic attraction and groove binding lead to no distinct variation in Tm. 
Thermal denaturation studies for sp-DNA should provide a means of gauging the 
efficacy of the compounds intercalation.  
In this work, the thermal denaturation curves of sp-DNA/curcumin and sp-
DNA/Ru-curc complex (10:1) mixtures were recorded in 10 mM PBS at pH 7.2. 
Figure 22 depicts the thermal denaturation curves for pure sp-DNA and for the 
mixtures sp-DNA/curcumin and sp-DNA/Ru-curc complex. The Tm values 
calculated for sp-DNA, sp-DNA/curcumin and sp-DNA/Ru-curc complex were 
84.8 ºC, 85.2 ºC and 92.2 ºC, respectively, as shown in Table 8. The variation on 
DNA melting temperature (ΔTm) values are also listed in Table 8. These ΔTm 
values were obtained from the midpoint of the melting curves of sp-DNA in the 
absence or presence of curcumin or Ru-curc complex.  
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Figure 22 - Comparison of the thermal denaturation curves for pure sp-DNA (grey), sp-
DNA/curcumin (orange) and sp-DNA/Ru-curc complex (blue) mixtures in 10:1 molar ratio. 
Curves were recorded under equilibrium conditions in 10 mM PBS at pH 7.2.  
 
As shown by the data of the Figure 22 and the Table 8, curcumin did not 
cause significant changes in the melting temperate of sp-DNA. Contrariwise, the 
mixture of sp-DNA with Ru-curc complex exhibits a dramatically higher melting 
temperature. The ΔTm value of 7.4 ºC in sp-DNA/Ru-curc complex mixture is 
indicative of an intercalative agent (ΔTm > 2 ºC) and reveals enhanced 
stabilization of the sp-DNA double-helix structure after intercalative binding.  
 
Table 8 – Comparison of thermal denaturation for pure sp-DNA, sp-DNA/curcumin or sp-
DNA/Ru-curc complex mixtures. The values for Tm were obtained from the midpoint of melting 
curves for pure sp-DNA, sp-DNA/curcumin and sp-DNA/Ru-curc complex mixtures (10:1). 
Mixture Tm (°C) ΔTm (°C) 
sp-DNA 84.8 — 
sp-DNA/Curcumin 85.2 0.4 
sp-DNA/Ru-curc complex 92.2 7.4 
 
The results of this section with those of section 3.5.1. (Absorption spectral 
studies) show that although curcumin binds to sp-DNA it does not form 
intercalative adducts with it and thus do not induce changes in denaturation 
temperature. On the other hand, the ruthenium complex has a binding constant 
similar to classical intercalators and, moreover, causes an increase in the 
denaturation temperature of sp-DNA. Thus, these results supported the fact that 
the Ru-curc complex can bind to sp-DNA by the mode of intercalation. This 
feature, makes this complex a potential anticancer agent.  
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3.6. Biological evaluation 
In order to assess the biological potential of the synthesized Ru-curc 
complex, its cytotoxic and photocytotoxic activities were evaluated using two 
human prostate cell lines: PNT-2 (non-neoplastic cell line) and PC-3 (neoplastic 
cell line, androgen-independent). Curcumin was used as a positive control, since 
it is a compound with confirmed cytotoxicity against several tumour cell lines.208 
 
3.6.1. Cellular Viability 
To determine the optimal working cell density for PNT-2 and PC-3 cell 
lines, the % AB reduction was followed in different cell densities up to 24 h in 
culture. The % AB reduction increased over culture time, starting from 1 h after 
addition of AB (Figure 23 for PNT-2 cell line and Figure 24 for PC-3 cell line).  
Based on these results, we decided to conduct further experiments using 
a cell density of 5000 cells per well, once cells were in the logarithmic phase at 
24 h. The incubation time was set at 72 h with base on literature reports on the 
cytotoxic evaluation of curcumin and structural analogues. Studies on prostate 
cancer cell lines (PC-3 and LNCaP) indicated that the cytotoxicity of curcumin is 
concentration dependent (higher concentrations of curcumin were more potent 
than the minor ones) and the cytotoxicity increase with the time of exposure of 
cells to curcumin (a longer duration of treatment was more potent than a short 
duration).209,210 
 
 
Figure 23 - Alamar Blue (AB) assay for PNT-2 cell viability. PNT-2 cells were seeded at 
varying densities in a 96-well plate. The AB solution (10% of cell culture volume) was added to 
the plate and relative absorbance units at 540 and 630 nm were measured at 1, 2, 4, 6, 8 and 24 
h.   
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Figure 24 - Alamar Blue (AB) assay for PC-3 cell viability. PC-3 cells were seeded at varying 
densities in a 96-well plate. The AB solution (10% of cell culture volume) was added to the plate 
and relative absorbance units at 540 and 630 nm were measured at 1, 2, 4, 6, 8 and 24 h.   
 
The inhibitory effects of curcumin and Ru-curc complex on the growth of 
cultured PNT-2 and PC-3 cells were determined by using the AB assay. Initially, 
PNT-2 and PC-3 cells were treated with various concentrations of curcumin and 
Ru-curc complex (20, 50 and 80 μM) for 72 h in the absence of light. The 
concentrations to test in this study were chosen based on both literature 
data209,210 and Ru-curc complex solubility which limited the maximum 
concentration to 80 μM.  
The inhibitory effects of different concentrations of curcumin and Ru-curc 
complex in cultured PNT-2 cells are presented in Figure 25. As shown in this 
figure, PNT-2 cell viability of cells treated with curcumin at 50 and 80 μM was 
significantly reduced compared with control (P-value<0.05 and P-value<0.001, 
respectively). On the other hand, Ru-curc complex has no cytotoxic effect on 
PNT-2 cells. Thus, curcumin has stronger inhibitory effect than Ru-curc complex 
as determined by AB assay.  
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Figure 25 - Effect of curcumin and Ru-curc complex on cell viability of PNT-2 cell line. PNT-
2 cells were treated with different concentrations of curcumin, Ru-curc complex or vehicle control 
DMSO at 1% for 72 h at 37 ºC in dark. The AB assay was used to determine cell viability. Data 
are representative of three independent trials and are expressed as the mean ± SD. *P-
value<0.05 and **P-value<0.001, compared to the group control.  
 
The inhibitory effects of different concentrations of curcumin and Ru-curc 
complex in cultured PC-3 cells are presented in Figure 26. As shown in figure, 
PC-3 cell viability of cells treated with curcumin at 50 and 80 μM was once again 
significantly reduced compared to control (P-value<0.001 and P-value<0.0001, 
respectively). Similarly to the results obtained for PNT-2 cells, the Ru-curc 
complex has no cytotoxic effect on PC-3 cells. Curcumin has stronger inhibitory 
effect than Ru-curc complex.  
 
Figure 26 - Effect of curcumin and Ru-curc complex on cell viability of PC-3 cell line. PC-3 
cells were treated with different concentrations of curcumin and Ru-curc complex or vehicle 
control DMSO at 1% for 72 h at 37 ºC in Dark. The AB assay was used to determine cell viability. 
Data are representative of three independent trials and are expressed as the mean ± SD. **P-
value<0.001 and ****P-value<0.0001, compared to the group control. 
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In the Figure 27 the effect of the curcumin on non tumoral PNT-2 cells is 
compared with that on PC-3 cells for evaluate the specificity of curcumin. Results 
show that curcumin is not specific, inhibiting the growth of tumoral and non-
tumoral cell lines in a similar fashion. Moreover, the statistical analysis 
corroborates these observations. As expected, this comparison was not made for 
the Ru-curc complex, once it showed no inhibitory effect on any of the two cell 
lines. 
 
Figure 27 - Effect of curcumin on cell viability of PNT-2 and PC-3 cell lines in dark 
conditions. PNT-2 and PC-3 cells were treated with different concentrations of curcumin or 
vehicle control DMSO at 1% for 72 h at 37 ºC in dark conditions. The AB assay was used to 
determine cell viability. Data are representative of three independent trials and are expressed as 
the mean ± SD. *P-value<0.05, **P-value<0.001 and ****P-value<0.0001, compared to the group 
control. 
 
Knowing that curcumin is a photosensitive compound, we decided to take 
advantage of this fact and assess their phototoxic potential in the cell lines used. 
Thus, were performed further studies comprising evaluation of the effects of 
curcumin and Ru-curc complex under exposure to white light (400-700 nm). PNT-
2 and PC-3 cells were treated with curcumin or Ru-curc complex, in the same 
concentrations of the experiment performed in absence of light, for 48 h, followed 
by illumination with white light at an irradiance of 10 mW/cm2 with a total light 
dose of 6 J/cm2. After 24 h, cells were examined for viability using AB assay.  
Figure 28 shows the experiment that evaluated the effect of combination 
of curcumin and light in PNT-2 cell viability. As shown, at curcumin concentrations 
at 50 and 80 μM in combination to light supressed PNT-2 cell viability but no 
growth effect was observed for the concentration of 20 μM, similarly to the results 
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obtained for the experiment in the absence of light. Indeed, these two results 
(light and dark) for 20 μM have no significant differences. In turn, for curcumin 
concentrations of 50 and 80 μM, statistical analysis indicated significante 
differences from light experiment (P-value<0.001 and P-value<0.0001) compared 
to the group control. Moreover, when comparing PNT-2 inhibition under dark and 
light conditions, statistical differences were found for the concentrations of 50 and 
80 μM (P-value<0.05). 
 
 
Figure 28 - Effect of curcumin on cell viability of PNT-2 cell line in dark and with irradiation. 
PNT-2 cells were treated with different concentrations of curcumin or vehicle control DMSO at 
1% for 72 h at 37 ºC in dark or with irradiation. The AB assay was used to determine cell viability. 
Data are representative of three independent trials and are expressed as the mean ± SD. *P-
value<0.05, **P-value<0.001 and ****P-value<0.0001, compared to the group control. 
 
Figure 29 shows the inhibitory effect of curcumin on PC-3 cell viability in 
the dark and light conditions. The results show that only at concentrations of 50 
and 80 μM of curcumin the PC-3 cell viability were significantly different when 
compared to the non-treated cells, both dark and light experiments. When 
comparing PC-3 inhibition under light and dark conditions, statistical differences 
were found only for the concentration up 50 μM (P-value<0.05).  
Overall, the results indicated that curcumin suppressed PNT-2 and PC-3 
cell proliferation in both dose- and light-dependent manner. We observed that 
curcumin in combination with white light displays a phototoxicity increased and 
can be consider as potential photosensitizer to treat prostate cancer. However, 
this study did not investigate which type of ROS were generated in curcumin-PDT 
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treatment and has been involved in cell death. Our results may provide a rationale 
for the potential use of curcumin in combination with white light as a 
chemopreventive agent for prostate cancer.  
All these results are in agreement with previously published ones for 
curcumin in combination with absence or presence of light for other human cell 
lines. Several reports demonstrated that curcumin is able to induce several cell 
death pathways and significantly inhibit cell growth, migration and invasion on 
several cell lines.211–213 Thus, the curcumin-mediated cell growth inhibition, in this 
study, could be due to the induced of the apoptosis or inhibition of cell 
proliferation. 
 
 
Figure 29 – Effect of curcumin on cell viability of PC-3 cell line in dark and with irradition. 
PC-3 cells were treated with different concentrations of curcumin or vehicle control DMSO at 1% 
for 72 h at 37 ºC in Dark or with irradiation whit white light at an irradiance of 10 mW/cm2 and a 
total light dose of 6 J/cm2. The AB assay was used to determine cell proliferation. Data are 
representative of three independent trials and are expressed as the mean ± SD. *P-value<0.05, 
**P-value<0.001 and ****P-value<0.0001, compared to the group control. 
 
Figure 30 shows a comparison of the effect of curcumin on PNT-2 and PC-
3 cells under light condition, to assess whether the light confers some specificity 
of the curcumin. Same as the results under dark conditions, the action with light 
shows that curcumin is not selective, inhibiting growth of the PNT-2 and PC-3 
cells in a similar percentage. These evidences were corroborated by statistical 
analysis.  
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Figure 30 - Effect of curcumin on cell viability of PNT-2 and PC-3 cell lines in light 
conditions. PNT-2 and PC-3 cells were treated with different concentrations of curcumin or 
vehicle control DMSO at 1% for 72 h at 37 ºC in light conditions. The AB assay was used to 
determine cell viability. Data are representative of three independent trials and are expressed as 
the mean ± SD. **P-value<0.001 and ****P-value<0.0001, compared to the group control.  
 
On the other hand, we evaluated phototoxic potential of the Ru-curc 
complex against PNT-2 and PC-3 cell lines and results are shown in Figure 31 
and Figure 32, respectively. Cells (PNT-2 and PC-3) were treated with complex 
and after 48 h of treatment were exposure to light. The results obtained point out 
that the Ru-curc complex was not toxic for PNT-2 as well as for PC-3 cell lines 
(up to 80 μM) either in dark or after exposure to light.  
These results were not expected since the complex is able to intercalate 
with the DNA and thus would be expected to have a cytotoxic effect. Moreover, 
several studies that used metal complexes of curcumin for anticancer activity 
demonstrated that curcumin in the metal-bound form retains its therapeutic 
potential.214,215 Further, these last authors found that various metals also have 
increased the stability of curcumin and their solubility under physiological 
conditions. A possible hypothesis to explain our results is that the compound does 
not enter into cells and thus, does not reach the nucleus. The non-entry of the 
Ru-curc complex into cells may be occurring due to their poor solubility under 
physiological conditions or because it cannot cross the cell membrane. However, 
we could not evaluate the uptake of the compound by the cells since this complex 
does not show fluorescence. 
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Figure 31 - Effect of Ru-curc complex on cell viability of PNT-2 cell line. PNT-2 cells were 
treated with different concentrations of Ru-curc complex or vehicle control 1% DMSO for 72 h in 
dark or exposure to white light at an irradiance of 10 mW/cm2 and a total light dose of 6 J/cm2 
light dose. The AB assay was used to determine cell proliferation. Data are representative of three 
independent trials and are expressed as the mean ± SD. 
 
 
Figure 32 - Effect of Ru-curc complex on cell viability of PC-3 cell line. PC-3 cells were 
treated with different concentrations of Ru-curc complex or vehicle control 1% DMSO for 72 h in 
dark or exposure to white light at an irradiance of 10 mW/cm2 and a total light dose of 6 J/cm2 
light dose. The AB assay was used to determine cell viability. Data are representative of three 
independent trials and are expressed as the mean ± SD. 
 
The IC50 values for curcumin are represented in Table 9. The activity of 
curcumin on the prostate cancer cell lines yields an IC50 value similar to that 
reported for other cell lines treated with curcumin in absence or presence of 
light.208 The IC50 values obtained from the curcumin in our two cell lines do not 
significantly differ. However, promising IC50 values were obtained in curcumin 
treatment under light conditions. Statistical analysis, confirm that the IC50 values 
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in dark and light conditions are significantly different but, the differences between 
two cell lines are not significant. For Ru-curc complex the IC50 could not be 
determined because the compound was not effective at any of the concentrations 
tested.  
 
Table 9 - The IC50 values (μM) of curcumin and Ru-curc complex towards PNT-2 and PC-3 
cell lines with and without light exposure. 
Condition tested PNT-2 PC-3 
Curcumin 
Dark 64.7 59.3 
Light 44.6* 45.8* 
Ru-curc complex 
Dark n.d. n.d. 
Light n.d. n.d. 
n.d. – not determined; the IC50 could not be determined because the Ru-curc complex Cl complex 
was not effective at any of the concentrations tested. * Extrapolated value since the minimum 
concentration tested was 50 μM.
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4.Conclusions and future prospects 
 
4.1. Conclusions 
In this work, curcumin was successfully isolated from Curcuma longa dry 
powder using column chromatography and its purity was confirmed by 1H and 13C 
NMR. The pure curcumin was used to prepare a new complex, identified as 
[Ru([9]aneS3)(curcumin)(S-DMSO)]Cl by elemental analysis, solution NMR and 
mass spectrometry. The complex was obtained in a 37% yield, which is 
somewhat low but still comparable with those of other ruthenium complexes with 
O-coordinated ligands, such as 7,3’,4’-trihydroxyflavone (38% yield), 3-methoxy-
5,7-dihydroxyflavone (23% yield) and 5,7-dihydroxyflavone (43% yield).216  
 
 
Figure 33 – Examples of O-coordinated ligands with ruthenium(II) metal centers. 
FL=flavonate.  
 
The present study reports that the new curcumin-ruthenium(II) binds to sp-
DNA by the mode of intercalation, supported by evidence from two assays. First, 
the new complex exhibits high binding affinity to sp-DNA with an intrinsic binding 
constant comparable to intercalative complexes. Moreover, the complex causes 
a dramatic increase in the sp-DNA melting temperature, a typical feature of 
intercalative complexes.  
Then, the in vitro cytotoxic action of Ru-curc complex was studied in the 
absence and presence of light using both healthy and tumoural prostate cell lines, 
respectively PNT-2 and PC-3, and using curcumin as a positive control. 
Surprisingly, the results of the assays show that the growth of both cell line was 
not influenced by treatment with Ru-curc complex even under light irradiation. 
Thus, it is necessary to evaluate the uptake of this complex in cells using, for 
instance, fluorescence probes (the herein reported studies did not evaluate cell 
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uptake of the compounds). Moreover, it is important to improve the solubility of 
the complex in physiological conditions which will allow to increase the 
concentrations to be tested. But, on the other hand, promising results were 
obtained for the phototoxic assay with curcumin. The results show that the growth 
of PNT-2 and PC-3 cells line was inhibited by curcumin in a concentration- and 
light dose-dependent manner.  
To conclude, it is our belief that this work focuses in a current subject and 
proposes the exploration of curcumin as a potential agent for treatment of 
prostate cancer in photodynamic therapy. Moreover, the most of the studies that 
evaluated the effect of curcumin on human tumour cells, used the mixture of 
curcuminoids commercially available but, in this study, all tests were made using 
pure curcumin obtained in the first part of the work.   
 
4.2. Future prospects  
The obvious follow-up of this work will be to test the cytotoxic activity of 
the new complex in different human cell lines (tumoural and non-tumoural), and 
try higher concentrations of the compound (after achieving the increase of the 
solubility of the compound in a physiological medium) and other dose and time of 
irradiation. Further, it will be important to explore other biological properties of the 
complex, namely its antibacterial activity and to evaluate the effect of light 
conditions in this activity, once several reports indicate that some metal 
complexes of curcumin have antibacterial properties and that this effect can be 
potentiated by irradiation.110 
Moreover, it is known from literature that the ruthenium(II)-curcumin 
derivatives with best anticancer activity are those with arene and 1,3,5-triaza-7-
phosphaadamantane (PTA). However, even though to confer greater solubility to 
derivatives, arene moiety is responsible for the poor solubility of the compound in 
a physiological medium. Thus, it would be interesting to synthesize other novel 
derivatives of ruthenium(II)-curcumin having as substituents the 9aneS3 and PTA. 
Thus, remain promising properties of macrocyclic effect and is still possible to 
increase the solubility of the complex. 
For the promising properties of curcumin as an agent for photodynamic 
therapy, is essential to study the application of lower concentrations, that are not 
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toxic in the dark, other times and light doses of the irradiation and also explore 
the application of the treatment of other cell lines. Moreover, is important making 
studies of the cellular localization of curcumin and evaluate the effect of curcumin 
in the cell death pathways.  
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Appendix 
Appendix 1: Calibration curves 
 
 
 
Figure A 1 – Calibration curve for determination of the molar absorptivity of the curcumin in 
DMSO. 
 
 
 
Figure A 2 – Calibration curve for determination of the molar absorptivity of the curcumin in 
DMF. 
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Figure A 3 – Calibration curve for determination of the molar absorptivity of the Ru-curc 
complex in DMSO. 
 
 
 
Figure A 4 - Calibration curve for determination of the molar absorptivity of the Ru-curc 
complex in DMF. 
 
